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ABSTRACT 
 
 
 Neuroblastoma (NB), the most common extracranial solid tumor in children, 
accounts for 15% of cancer-related deaths in pediatric patients.  Caspase-8 (casp8), a 
proapoptotic protein, is silenced in approximately, 50-70% of neuroblastoma patient 
samples.  Loss of casp8 has been suggested to increase NB metastasis and correlated, in 
some studies, with advanced-stage NB.  Furthermore, decreased casp8 expression may 
facilitate neuroblastoma tumorigenesis by protecting cells from cell death mediated by 
either integrins or chemotherapeutics.  Paradoxically, casp8 expression is maintained in 
30-50% of NB patient samples giving rise to the possibility that casp8 may provide 
selective advantages for NB tumorigenesis.  Caspase-8 is shown to increase tumor cell 
adhesion, migration and growth.  This drives the question as to how a single protein can 
promote very opposing functions.  One possible explanation is that post-translational 
modifications may decrease the catalytic activity of casp8 and shift its role towards 
survival.  Caspase-8 has been shown to be phosphorylated by SRC, thus decreasing its 
apoptotic function and increasing ERK signaling, which supports our hypothesis.  Ataxia 
telangiectasia mutated kinase (ATM), an essential mediator in the DNA double strand 
break repair mechanism, is activated by chemotherapeutic treatments, radiation, and 
cellular stress.  Caspase-8 has one consensus phosphorylation site that has been reported 
to be phosphorylated in a genome-wide screen for ATM substrates.  Here, we tested 
whether casp8 expression enhanced primary NB tumorigenesis and whether modulation 
of casp8 by phosphorylation altered its biological function in NB.  For the first time, this 
study demonstrates that casp8 enhances orthotopic xenograft tumor establishment in low 
tumorigenic neuroblastoma cells; which, may explain why casp8 expression is 
maintained in some NB tumors.  Furthermore, exposure to DNA damaging agents 
suppresses the apoptotic function of casp8 via ATM-mediated phosphorylation, thereby 
shifting the balance between the proapoptotic and prosurvival functions towards cell 
survival.  This outlines a possible mechanism by which tumor cells may avoid cell death 
when exposed to chemotherapeutic agents. 
  
 vi 
TABLE OF CONTENTS 
 
CHAPTER 1. INTRODUCTION .....................................................................................1 
Neuroblastoma .................................................................................................................1 
Cell Death ........................................................................................................................2 
Caspase-8 .........................................................................................................................2 
Nonapoptotic functions of caspase-8 ...........................................................................8 
Caspase-8 in cancer ....................................................................................................11 
Role of caspase-8 in neuroblastoma...........................................................................13 
Specific Aims .................................................................................................................14 
CHAPTER 2. CASPASE-8 PROMOTES NEUROBLASTOMA 
TUMORIGENESIS .........................................................................................................17 
Introduction ....................................................................................................................17 
Results ............................................................................................................................19 
Caspase-8 expression promotes NB tumor growth in low tumorigenic cells ............19 
Caspase-8 increased tumor engraftment and growth in NB7 cells ............................21 
Loss of caspase-8 affects tumor engraftment .............................................................23 
Tumorigenesis does not require the proteolytic activity of caspase-8 .......................24 
Catalytically inactivated caspase-8 did not enhance tumor engraftment ...................24 
The protumorigenic function of caspase-8 is dependent on the prodomain ..............26 
Lack of the N-terminal prodomain suppresses tumor growth ...................................29 
Overall expression of caspase-8 is diminished in orthotopic xenografts ...................29 
Discussion ......................................................................................................................32 
Materials and Methods ...................................................................................................38 
Cell lines ....................................................................................................................38 
Reagents .....................................................................................................................38 
Immunoblotting ..........................................................................................................38 
MTT ...........................................................................................................................39 
Orthotopic xenograft ..................................................................................................39 
RT-PCR ......................................................................................................................40 
CHAPTER 3. ROLE OF CASPASE-8 PHOSPHORYLATION IN 
NEUROBLASTOMA ......................................................................................................41 
Introduction ....................................................................................................................41 
Results ............................................................................................................................44 
DNA damage promotes caspase-8 phosphorylation ..................................................44 
ATM-mediated phosphorylation of caspase-8 ...........................................................44 
Caspase-8 phosphorylation is a cytoplasmic event ....................................................47 
Serine 219 of caspase-8 suppresses the catalytic activity ..........................................49 
3D culture demonstrated increased colony formation ...............................................49 
Role of caspase-8 phosphorylation in NB tumorigenesis ..........................................52 
Regulation of caspase-8 .............................................................................................55 
Discussion ......................................................................................................................55 
Materials and Methods ...................................................................................................59 
 vii 
Cell lines ....................................................................................................................59 
Reagents .....................................................................................................................59 
Immunoblotting ..........................................................................................................60 
Colony formation .......................................................................................................60 
MTT ...........................................................................................................................61 
In vitro kinase assay ...................................................................................................61 
Cell fractionation .......................................................................................................61 
RT-PCR ......................................................................................................................62 
Caspase-8 enzymatic assay ........................................................................................62 
Orthotopic xenograft ..................................................................................................62 
CHAPTER 4. OVERALL SUMMARY AND FUTURE EXPERIMENTS ...............64 
Summary ........................................................................................................................64 
Future Directions ...........................................................................................................68 
Mechanism of caspase-8 during tumorigenesis .........................................................68 
Phosphorylation of caspase-8 ....................................................................................70 
LIST OF REFERENCES ................................................................................................71 
APPENDIX.  CHAPTER 3 SUPPLEMENTAL FIGURES .........................................83 
VITA..................................................................................................................................86 
  
 viii 
LIST OF FIGURES 
 
Figure 1-1. Representation of the caspase-8 family and caspase-8. ..................................3 
Figure 1-2. Outline of the roles of caspase-8 in various cell death pathways. ..................5 
Figure 1-3. Caspase-8 mode of activation. ........................................................................7 
Figure 1-4. Prosurvival mechanisms of caspase-8. ...........................................................9 
Figure 1-5. Domain specific functions of caspase-8. ......................................................10 
Figure 1-6. Role of caspase-8 expression levels promote tumorigenesis and 
metastasis. ....................................................................................................15 
Figure 2-1. Caspase-8 increased neuroblastoma tumorgenicity. .....................................20 
Figure 2-2. Increased engraftment in caspase-8 positive NB7 cells. ...............................22 
Figure 2-3. Catalytic activity of casp8 suppressed tumor growth. ..................................25 
Figure 2-4. Inactivated of caspase-8 did not enhance tumor engraftment. ......................27 
Figure 2-5. The prodomain is essential for caspase-8 tumorgenicity. .............................28 
Figure 2-6. The N-terminal prodomain is required for tumor growth. ............................30 
Figure 2-7. Caspase-8 is diminished in orthotopic xenografts. .......................................31 
Figure 2-8. Overall expression of caspase-8 is diminished in orthotopic xenografts. .....33 
Figure 3-1. Caspase-8 phosphorylation at S219 post DNA damage. ..............................45 
Figure 3-2. Caspase-8 phosphorylation at S219 is ATM dependent. ..............................46 
Figure 3-3. Phosphorylation of caspase-8 is a cytoplasmic event. ..................................48 
Figure 3-4. Phosphorylation at S219 suppresses caspase-8-mediated apoptosis. ...........50 
Figure 3-5. Phosphorylation increased colony formation and growth. ...........................51 
Figure 3-6. Phosphorylation of caspase-8 did not enhance tumorigenesis. .....................53 
Figure 3-7. Phosphorylation did not affect tumor engraftment. ......................................54 
Figure 3-8. Posttranslational regulation of caspase-8 in S219A and S219E mutated 
caspase-8 expressing NB7 cells. ..................................................................56 
 ix 
Figure 4-1. Role of caspase-8 in neuroblastoma. ............................................................66 
Figure 4-2. Model of caspase-8 induced signaling. .........................................................67 
Figure A-1. Serine 219 of caspase-8 is highly conserved. ...............................................83 
Figure A-2. Caspase-8 phosphorylation in apoptosis, adhesion and tumor growth. ........84 
Figure A-3. Caspase-8 expression does not affect cell cycle. ..........................................85 
  
 x 
LIST OF ABBREVIATIONS 
 
 
γ-IFN gamma interferon 
ATG7 autophagy-related gene 7 
ATM ataxia telangiectasia mutated 
BRCA1 breast cancer 1, early onset 
CARM chick chorioallantoic membrane 
CARMA 1 caspase recruitment domain membrane-associated guanylate 
kinase protein 1  
Cdk1 cyclin-dependent kinase 1 
Chk1 checkpoint kinase 1 
Chk2 checkpoint kinase 2 
cIAP cellular inhibitor of apoptosis protein 1 
CUL3 cullin3 
DD death domain 
DED death effector domain 
DISC death-inducing signaling complex 
DR4 death receptor 4 
ECM extracellular matrix 
EGF epidermal growth factor 
FADD fas-associated protein with death domains 
FLIP FLICE-inhibitory protein 
G6PDH glucose-6-phosphate dehydrogenase 
HIF-1 hypoxia-induced factor 1 
HNSCC head and neck squamous cell carcinoma 
HSP27 heat-shock protein 27 
IKK IkappaB kinase 
IMD integrin-mediated death 
INSS international neuroblastoma staging system 
KAP-1 KRAB-associated protein 1 
Malt 1 mucosa-associated lymphoid tissue lymphoma translocation gene 1 
MKI mitotic cells versus karyorrhexis 
MOMP mitochondrial outer membrane permeabilization 
mTORC1 mTOR complex 1 
NADPH nicotinamide adenine dinucleotide phosphate-oxidase 
NEMO NF-кB essential modulator 
NF-кB nuclear factor kappa B 
PARP2 poly (adenosine diphosphate-ribose) polymerase 2 
Phox2b paired-like homeobox 2B 
PI3K phosphatidylinositol 3-kinase 
PIKK phosphoinositide 3-kinase-related kinase 
RIP1 receptor-interacting protein 1 
RIP3 receptor-interacting protein 3 
ROS radical oxygen species 
RSK2 ribosomal S6 kinase 2 
 xi 
SCID severe combined immunodeficiency 
TNF tumor necrosis factor 
TNFR1 tumor necrosis factor receptor 1 
TRADD tumor necrosis factor receptor-associated death domain 
TRAF2/5 tumor necrosis factor associated factor 2/5 
TRAF6 tumor necrosis factor receptor associated factor 6 
TRAIL tumor necrosis factor-related apoptosis-inducing ligand 
TrkA tropomyosin-receptor-kinase A 
TrkB tropomyosin-receptor-kinase B 
TSC2 tuberous sclerosis complex 2 
zVAD benzyloxycarbonylvalyl-alanyl-aspartic acid (O-methyl)-fluoro-
methylketone) 
4E-BP1 eIF-4E-binding protein 1 
53BP1 p53-binding protein 1 
 
 1 
CHAPTER 1.    INTRODUCTION 
 
 
Neuroblastoma 
 
 Neuroblastoma (NB) is the most common extracranial solid tumor diagnosed in 
children accounting for 7 to 10% of pediatric cancers and 15% of cancer-related deaths 
[1-4].  NB, considered to be a disease of the sympathetic nervous system, is derived from 
neural crest cells of the sympaticoadrenal lineage.  Sympaticoadrenal cells give rise to the 
medullary region of the adrenal gland and the sympathetic ganglia [5, 6].  NB may 
develop anywhere along the sympathetic axis including the neck (5%), chest (20%), 
pelvis (5%), and abdominal cavity (65%) of which the adrenal medulla is the most 
common site of tumorigenesis [3, 7, 8]. 
 
 The International Neuroblastoma Staging System (INSS) classifies NB into six 
distinct stages including stage 1, 2a, 2b, 3, 4 and 4s [3, 4, 8].  Early stage NB (stages 1, 2) 
are localized tumors clinically treated with irradiation and chemotherapy.  Stages 3 and 4 
are metastatic disease and are often resistant to chemotherapy.  In contrast, 4s tumors are 
metastatic yet regress spontaneously without clinical intervention [7, 9].  Further 
classification of NB includes the level of Schwannian stromal content, age at which the 
patient is diagnosed, and the number of mitotic versus necrotic cells (karyorrhexis) [10].  
Approximately, 75% of children presenting with advanced stage NB are older than 1 year 
of age [3, 11].  Diagnosis and overall prognosis of NB is extremely variable based on 
age, tumor location, metastasis, and tumor heterogeneity.  The overall five-year survival 
rate of NB patients has increased; however, patients diagnosed with advanced-stage NB 
have only shown slight improvements with less than a 40% long-term survival rate 
despite advances in chemotherapeutic treatments over the last few decades [8]. 
 
 Several genetic abnormalities have been associated with NB tumorigenesis.  
Familial NB only accounts for 5% of NB deriving from germline mutations in the paired-
like homeobox 2B (PHOX2b) gene and a receptor tyrosine kinase known as ALK [12].  
Amplification of the MYCN proto-oncogene occurs in approximately 33% of NB 
patients.  Chromosomal deletion or rearrangement of 1p36 (26%), 2q33 (30%), 11q23 
(44%), 14q23 (44%) and gain of 17q23 (50%) are also associated with NB [13].  
Favorable prognosis is linked to near-triploidy status and expression of neurotrophin 
receptor known as tropomyosin-receptor-kinase A (TrkA).  Poor prognosis may result 
from neurotrophin receptor TrkB expression, loss of 1p, 11p, and gain of 17q [3, 14-17].  
A hallmark of advanced-stage NB is the amplification of the 2p24 locus leading to high 
levels of N-Myc.  N-Myc, a transcription factor, leads to dysfunctional cell growth when 
overexpressed.  MYCN is amplified in 33% of advanced-stage NB leading to a 3-year 
survival rate of only 30% [3, 18].  The exact mechanism of how MYCN amplification is 
associated with poor prognosis is still unclear.  Research suggests that MYCN 
amplification may require deregulation of the apoptotic machinery in order to survive, 
since N-Myc sensitizes NB cells to death receptor-mediated apoptosis via casp8 
activation [19].  Although it remains unclear as to which tumor suppressor genes reside in 
the above mentioned chromosomal regions, p16INK4a, pRb, p53, and p14ARF are not 
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commonly mutated or deleted in NB [3, 8, 13, 20, 21].  Additional research into the 
genetic abnormalities of NB is required. 
 
 
Cell Death 
 
 Programmed cell death (PCD), first recognized by Lockshin and Williams as a 
regulated and defined process, is an essential process in normal development, cellular 
differentiation, and maintaining homeostasis [22-24].  The three types of PCD are 
apoptosis, autophagy and necrosis, otherwise known as programmed necroptosis.  
Differences in PCD are characterized by cellular morphology as well as protein signaling 
pathways.  Morphologically, apoptosis is characterized by condensation of the chromatin, 
cell shrinkage, and blebbing of the plasma membrane.  Autophagic cell death lacks 
chromatin condensation, but produces autophagic vacuoles within the cytoplasm.  
Necroptosis is associated with cytoplasmic swelling, breakdown of the cellular 
membrane, and moderate chromatin condensation [25-27].  Each form of programmed 
cell death is regulated by various signaling pathways and biochemical processes.  
Importantly, caspase-8 (casp8) plays a role in each type of cell death pathway. 
 
 
Caspase-8 
 
 Cysteine-aspartyl specific proteases, or caspases, are the essential drivers of 
apoptosis.  As the name denotes, caspases are proteases that target substrate-specific 
aspartic acid residues.  The caspase family consists of 14 different caspases categorized 
as either inflammatory, apoptotic or having no known function [25, 28, 29].  The 
apoptotic subgroup is further divided into initiator or executioner caspases.  Initiator 
caspases are the first caspases to be activated during apoptosis.  Executioner caspases are 
activated by an initiator caspase and further transduce the apoptotic signal [28, 30, 31] 
(Figure 1-1A). 
 
 The CASP8 gene located on chromosome 2q33-34 encodes for the casp8 protein 
[32, 33].  Caspase-8 contains an N-terminal prodomain comprised of two death-effector 
domains (DED) which bind to adaptor proteins by hemophilic interactions [34, 35].  The 
C-terminal domain of casp8 consists of a large and small subunit separated by a short 
linker sequence [36].  The large subunit (p18) of the catalytic domain contains two 
essential catalytic dyads, a cysteine and a histidine (Figure 1-1B).  These dyads are 
required for internal cleavage between subunit domains and subsequent activation of 
casp8.  The small catalytic subunit produces the substrate-binding site [28, 30, 37, 38].  In 
the cell, casp8 is expressed as an inactive zymogen; however, some reports have 
demonstrated that casp8 may have some activity in its zymogenic form [39, 40]. 
 
 Morphological changes induced by autophagy are well characterized though 
poorly understood mechanistically.  Research performed by Yu et al. back in 2004 
showed that exposure of mouse L929 fibroblast cells to a broad caspase inhibitor known 
as zVAD (benzyloxycarbonylvalyl-alanyl-aspartic acid (O-methyl)-fluoro-methylketone)  
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Figure 1-1. Representation of the caspase-8 family and caspase-8. 
(A)  The caspase family is divided into three different subgroups based on mode of 
activation.  Caspase-8 is a categorized as an initiator caspase.  (B)  Caspase-8 consists of 
an N-terminal prodomain and a C-terminal catalytic domain.  The prodomain contains 
two death effector domains (DED) and the large and small subunits form the catalytic 
domain.  The linker region between the prodomain and catalytic domain contains three 
cleavable aspartic acid residues.  The linker region between the two catalytic subunits 
contains two cleavable residues [41]. 
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induced autophagic cell death [42].  Yu et al. further showed that the inhibition of casp8 
was critical in order to induce autophagy mediated by ATG3 (autophagy-related gene 7) 
and beclin-1 [42].  Validation of the involvement of casp8 in autophagy came from 
studies showing that casp8 mediated the cleavage and subsequent inactivation of ATG3 
and beclin 1 [43, 44]. During TNF-related apoptosis-inducing ligand (TRAIL)-induced 
autophagy, the large catalytic subunit of casp8 was found to be degraded by the 
autophagosome [44, 45].  These results suggest crosstalk between apoptosis and 
autophagy (Figure 1-2). 
 
 Necroptosis is initiated at the plasma membrane by ligand bound death receptors 
(i.e. TNFR1, CD95, and TRAILR1) [26].  Briefly, TNFα (tumor necrosis factor) binds to 
the TNFR1 death receptor (tumor necrosis factor receptor 1) which then recruits the 
adaptor protein TRADD (TNFR-associated death domain), RIP1 (receptor-interacting 
protein 1), and other mediators like TRAF2/5 (TNF associated factor) and cIAP2 
(cellular inhibitor of apoptosis protein) [46, 47].  Internalization of the receptor bound 
complex promotes removal of TRAF2/5 and cIAP2 and recruitment of FADD (Fas-
associated protein with death domains) and casp8.  Caspase-8 recruitment and subsequent 
activation mediates apoptosis and blockage of necrosis through the cleavage of RIP1 and 
RIP3.  In contrast, blockage of casp8 promotes RIP1 and RIP3 phosphorylation and 
formation of the necrosome comprised of TNFR1/TRADD/RIP1/RIP3/FADD [47-49] 
(Figure 1-2). 
 
 The apoptotic signaling pathway is initiated at either the mitochondria or plasma 
membrane.  The intrinsic apoptotic pathway is initiated at the mitochondria by various 
cellular stressors.  Cell death promoted at the mitochondria induces activation of caspase-
9 and subsequent formation of the apoptosome [50].  Death receptor-mediated apoptosis, 
known as the extrinsic apoptotic signaling pathway, is transduced by casp8; which is the 
key initiator caspase of the extrinsic apoptotic pathway [51].  Death promoting ligands 
(i.e. FasL and TRAIL) induce the extrinsic apoptotic pathway by binding to death 
receptors (i.e. FasR, DR4).  Ligand binding to their respective death receptor induces 
receptor trimerization and subsequent recruitment of the adaptor protein known as FADD 
[35, 52].  The death domain (DD) of FADD binds to the DD domain of the receptor 
followed by casp8 binding to the DED domain of FADD.  Additional recruitment of a 
monomeric casp8 to FADD provides a platform for homodimerization and formation of 
the death-inducing signaling complex (DISC) [40, 53].  Recent research suggests that 
dimerization and not autocleavage is essential for full catalytic activity [54-56].  
Dimerization of casp8 induces a conformational change in the flexible linker region 
between the large and small catalytic subunits.  These structural alterations reveal the 
active site; therefore demonstrating that uncleaved casp8 has basal levels of activity.  
Dimerization promotes proximity induced auto-proteolysis at specific aspartic acid 
residues.  These cleavage events reduce steric hindrance, increase stability, and induce 
full catalytic activity [39, 57, 58].  Removal of the prodomain releases the catalytic 
subunits from the DISC into the cytosol.  The large and small catalytic subunits, linked 
by hydrophobic interactions, undergo cleavage of the linker region between the two 
subunits which is thought to induce the formation of the catalytic and substrate binding 
sites [30, 38, 57].  Polyubiquitination of casp8 by CUL3/RBX1 promotes p62 binding  
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Figure 1-2. Outline of the roles of caspase-8 in various cell death pathways. 
This simplified overview depicts the possible roles of casp8 in cell death.  Activation of 
various cell surface receptors or cellular stress can induce multiprotein complex 
formation that drives apoptosis, autophagy, and necroptosis.  Induction of one death 
pathway over another depends on casp8 localization, expression levels of the various 
proteins within the complexes, and level of inhibitor proteins.  Further research is 
required to fully understand the upstream and downstream mechanisms of these pathways 
and the role that casp8 plays in each. 
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and translocation to cytosolic “aggresomes” (Figure 1-3).  This ubiquitination and 
translocation enhances casp8 activity and stability [59]. 
 
 The expression levels of antiapoptotic Bcl-2 proteins are thought to regulate the 
downstream effects of active casp8 [60].  Type I cells or low expressing antiapoptotic 
Bcl-2 proteins, induce casp8-mediated apoptosis through the cleavage of executioner 
caspases (caspase-3, 6, and 7) and PARP (poly adenosine diphosphate-ribose 
polymerase) [61, 62].  Cells expressing higher levels of the antiapoptotic Bcl-2 proteins, 
or type II cells, mediate apoptosis through the cleavage of BID by caspase-8 [63].  
Truncated BID (tBID) induces mitochondrial outer membrane permeabilization (MOMP) 
and subsequent cytochrome c release, apoptosome formation, and cell death [60, 63].  
Importantly, casp8 has been shown to be critical in the transduction of the apoptotic 
signaling cascade while regulating the autophagic and necrotic cell death pathways 
(Figure 1-2). 
 
 Caspase-8 may also heterodimerize with cellular and viral forms of FLIP (FLICE-
inhibitory protein).  FLIP was first identified in gamma-herpes viruses (v-FLIP) by 
Thorne et al, and Hu et al who later discovered a cellular homolog of v-FLIP (c-FLIP) 
which produces two FLIP isoforms known as c-FLIPL and c-FLIPS [64, 65].  v-FLIP and 
c-FLIPS both contain two DED domains yet lack the catalytic domain.  Upon DISC 
recruitment, v-FLIP and c-FLIPS, short form, heterodimerize with casp8 and therefore, 
block casp8–mediated apoptosis.  c-FLIPL is the longer isoform of c-FLIP, which 
contains two DED domains and the large and small subunits of the catalytic domain.  
However, c-FLIPL lacks the enzymatically essential cysteine residue within the large 
catalytic subunit rendering c-FLIPL catalytically inactive [66].  Initially, c-FLIPL 
function in cell death was controversial.  Several groups demonstrated that c-FLIPL 
inhibited casp8-mediated cell death while others showed that it promoted casp8 activity 
[66-69].  Additional research showed that the role of c-FLIPL in cell death was 
dependent on expression levels [70, 71].  Overexpression leads to c-FLIPL binding to all 
the caspase-8 binding sites and subsequently blocking apoptosis while physiological 
levels promoted heterodimerization and promoted casp8 activity [70, 71].  Interestingly, 
studies have revealed that the casp8/c-FLIPL heterodimer is primarily involved with pro-
survival functions within the cell.  Kataoka et al demonstrated that the caspase-8 
heterodimer promoted activation of the NF-κB pathway [72].  TNFα-induced necroptosis 
via FADD-RIP1-RIP3 was blocked by casp8/c-FLIPL heterodimers [73].  Studies have 
shown that the casp8/c-FLIPL heterodimer contains enzymatic activity but targets 
different substrates.  For example, the heterodimer has been shown to cleave c-FLIP, 
casp8, RIP, and HDAC7 as opposed to caspase-3, bid, or other proapoptotic proteins [74-
78].  These results demonstrate a possible mechanism that cancer cells may induce to 
avoid the proapoptotic function of casp8. 
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Figure 1-3. Caspase-8 mode of activation. 
Caspase-8 is maintained within the cell as an inactive zymogen.  Activation of the 
extrinsic apoptotic pathway induces the recruitment of casp8 binding to the adaptor 
protein known as FADD via hemophilic interactions.  Dimerization induces 
conformational changes of the linker region allowing for basal catalytic activity.  
Subsequent polyubiquitination increases caps8 stability while the autoprocessing (yellow 
stars) of casp8 separates its recruitment domain and the catalytic subunits.  Release of 
casp8 from the DISC mediates casp8 translocation to cytosolic ubiquitin rich 
“aggresomes”. 
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Nonapoptotic functions of caspase-8 
 
 Ongoing research supports that casp8 is a multifunctional and multipurpose 
protein with often opposing roles in development and tumorigenesis (Figure 1-4).  
Interestingly, several of these functions are independent of the proteolytic activity of 
casp8 and the catalytic domain altogether (Figure 1-5).  Caspase-8 has been reported to 
be involved in cellular growth through cell cycle regulation, proliferation, survival, and 
metastasis.  Defects in cellular proliferation have been observed in fibroblasts, 
hepatocytes following partial hepatectomy, and in hematopoietic progenitor cells 
deficient in casp8 [79-81].  Bone-marrow cells of conditional casp8 knockout mice 
lacked the ability to form myeloid or B lymphoid colonies after exposure to IFN [82].  
Caspase-8 deficiency also led to a blockage of macrophage differentiation in the 
myelomonocytic lineage [82].  The lack of casp8 expression in endothelial cells resulted 
in deregulated vasculature and embryonic death [82].  Deficiency of casp8 in T cells has 
been associated with immunodeficiency, abolished proliferation upon antigen activation, 
and defects in immune homeostasis [83-85].  Furthermore, casp8 regulated the 
phosphorylation of ribosomal protein S6, thereby controlling the G1/S cell cycle 
transition [86]. 
 
 Tumor cell invasiveness, migration, and adhesion have also been contributed to 
casp8 expression. For example, Finlay et al. demonstrated that the “RXDLL motif” 
within the DED domain of casp8 was crucial for the activation of ERK1/2 by epidermal 
growth factor (EGF) independent of the proteolytic activity of casp8 [87].  Calpain 2-
mediated processes such as detachment, Rac activation, lamellipodia formation, and 
adhesion turnover were lower in casp8 null cells suggesting that casp8 may drive calpain 
2 activation [88-90].  Furthermore, integrin ligation induced Rac and Rab5 activation in a 
casp8-dependent manner [91].  Caspase-8 has been shown to be involved in survival 
signaling pathways such as Erk1/2, phosphatidylinositol 3-kinae (PI3K), and NF-κB 
(nuclear factor kappa B).  The DED domain of casp8 also has been shown to induce NF-
κB activation [92].  Additional studies demonstrate that catalytically inactive casp8 also 
leads to NF-κB activation [93, 94].  In B cells casp8 has been observed to interact with 
the IKKαβ (IkappaB) complex [95].  In T cells casp8 association with Bcl10, Malt1 
(mucosa-associated lymphoid tissue lymphoma translocation gene), CARMA 1 (caspase 
recruitment domain membrane-associated guanylate kinase protein), IKK complex and 
TRAF6 leads to the ubiquitination and subsequent localization of casp8 to the lipid rafts 
[96].  Mutation of the PI3K catalytic subunit induced TRAIL and CD95L-mediated 
activation of NF-κB and casp8, thereby leading to morphological changes and ROCK 
activation [97].  In addition, casp8 expression levels are regulated during the wound 
healing process.  RNA levels of casp8 proximal to the wound site were found to be 
significantly lower than those distant from the wound.  Caspase-8 RNA levels returned to 
normal levels once the wound healed [98].  This data suggests that the functions of casp8 
in various nonapoptotic and apoptotic pathways may be closely regulated and maintained. 
 
 It has been hypothesized that the various roles of casp8 may be regulated by 
localization, involvement with various macromolecular complexes, and/or 
posttranslational modifications [90, 99, 100].  Cursi et al was the first to show that EGF- 
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Figure 1-4. Prosurvival mechanisms of caspase-8. 
Noncanonical activation of casp8 by substrate ligation to integrins, toll-like receptors, 
growth receptors, immune receptors, and death receptors may promote casp8 mediated 
cell survival signaling.  Intrinsic cellular stress may also induce casp8-mediated cell 
survival.  Antiapoptotic functions of casp8 depend primarily on upstream activation of 
kinases and protein expression levels of protein complexes.  The complete mechanistic 
functions of phosphorylated casp8 and protein-protein formations are unclear and further 
research is needed. 
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Figure 1-5. Domain specific functions of caspase-8. 
The scheme depicts the possible functions induced by either the catalytic domain or death 
effector domain (DED) of casp8 in response to catalytic stimuli thereby required the 
catalytic activity (red dots) casp8.  In contrast, the catalytic domain of casp8, independent 
of its catalytic capabilities, may activate various proteins, translocate, and/or induce 
cellular motility.  The DED domains contain no proteolytic capabilities; however, DED 
domains independent of the C-terminal catalytic domain may promote various signaling 
pathways. 
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mediated migration induced casp8 phosphorylation by Src at tyrosine 380 [101].  This 
phosphorylation induced casp8 interactions with the p85 subunit of the 
phosphatidylinositol 3-kinase thereby increasing migration and adhesion.  Later, Barbero 
et al. demonstrated that integrin ligation could also induce casp8 phosphorylation at 
tyrosine 380 and promote the localization of casp8 to the lamellae of migrating cells 
[102].  In addition, Cursi et al. further demonstrated that the phosphorylation event at 
tyrosine 380 suppressed the catalytic activity of casp8 [101]. Caspase-8 phosphorylation 
by cyclin-dependent kinase 1 (Cdk1) and ribosomal S6 kinase 2 (RSK2) at serine 387 and 
threonine 263 respectively, lead to a decrease in Fas-mediated apoptosis [103, 104].  
Furthermore, p38MAPK phosphorylation of casp8 at serine 347 also suppressed the 
catalytic activities of casp8 [105].  The DNA damage repair protein, ataxia telangiectasia 
mutated (ATM) kinase was reported to phosphorylate casp8 at serine 219 upon double 
strand DNA breaks [106].  In cancer, several of these kinases are reported to be 
upregulated due to their pro-survival function; hence, they may contribute to altering the 
balance between the canonical function of caspases to a more noncanonical or pro-
survival function [107]. 
 
 Primarily, casp8 was considered as a cytoplasmic protein due to its role in 
apoptosis; however, research reveals that, in neurons, the active form of casp8 (p46) may 
enter the nucleus [108].  In human fibroblasts and mouse striatal cells, casp8 is shown to 
be localized primarily in the mitochondria and partially in the nucleus [109].  
Furthermore, active casp8 (p18/p10) cleaves PARP2 within the nucleus during ischemia-
induced apoptosis [110].  The DED domains bind to the perinuclear microtubules during 
paclitaxel-mediated apoptosis and during differentiation of skin and myeloid cells [111, 
112].  Besnault-Mascard et al. suggested that sumoylation of casp8, at lysine 156 induced 
nuclear localization [113].  As previously stated, casp8 may localize at the lamella and 
lipid rafts [96, 102].  Collectively, this data strongly suggests that cell type and cellular 
conditions may influence casp8 function and localization. 
 
 
Caspase-8 in cancer 
 
 Defective apoptotic machinery, a common characteristic of cancer cells, is 
associated with tumorigenesis and therapeutic resistance [114].  Teitz et al. and others 
have demonstrated that casp8 is preferentially silenced in NB cell lines and patient 
samples though rarely deleted [17, 115-117].  Loss of casp8 has also been shown in other 
tumors including small cell lung carcinoma, rhabdomyosarcoma, glioblastoma, 
retinoblastoma, medulloblastoma, Wilms tumors and colorectal carcinomas [118-123]. 
 
 Suppression of casp8 expression resulted from the hypermethylation at the exon 
3-intron 3 region, upstream of the protein translation start site [17].  A study of 180 
pediatric tumors revealed that the exon 3-intron 3 region of the CASP8 gene was 
methylated in 83% of rhabdomyosarcomas, 81% medulloblastomas, 59% 
retinoblastomas, 52% neuroblastomas, and 19% in Wilms tumors [118].  The 
hypermethylation of casp8 showed a statistically significant  correlation with relapse 
susceptibility, a decreased overall survival rate, and an increase in resistance against 
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death receptor-mediated apoptosis and some chemotherapeutics [116, 123-127].  Studies 
demonstrated that by using demethylating reagents such as, gamma interferon (γ-IFN), 
5’-aza-2-deoxycytidine, or retinoic acid, casp8 expression could be restored [127-130]. 
 
 In addition to methylation, casp8 deficiency may also contribute to protein 
mutation, though to a lesser extent.  Only 5% of colorectal carcinomas and 13% of 
hepatocellular carcinomas exhibited mutated casp8.  To date, there have been five 
reported mutations of casp8: a frameshift mutation at position 1381, three missense 
mutations (R413G, Q366H, and R162I), and one nonsense mutation resulting in a 
truncated form of casp8 [120, 122, 131]. 
 
 The role of casp8 in tumorigenesis and overall patient survival remains unclear.  
For example, Strater et al. reported that casp8 expression was correlated with a decrease 
in the long-term survival rate of patients with colon carcinoma [132].  In head and neck 
squamous cell carcinoma (HNSCC) it was shown  that casp8 expression was correlated 
with a better prognosis; although, HNSCC with lymph node metastasis casp8 expression 
was significantly associated with a poorer survival rate and outcome [133].  This data 
suggests that the balance between the various functions of casp8 may be altered based on 
tumor type and the stage of tumor growth. 
 
 Several strategies have been developed to upregulate casp8 and promote casp8 as 
a potential therapeutic target for cancer therapy.  As previously stated, due to the high 
frequency of casp8 methylation in cancers, one possible method consists of using the 
demethylating agent, 5-aza-2’deoxycytidine (5-Aza) [116, 130].  This treatment increased 
casp8 expression in several tumors presenting with epigenetically silenced casp8 
including NB [134-136].  Furthermore, the casp8 promoter region contains interferon-
sensitive response elements that regulate casp8 expression [137, 138].  Accordingly, 
exposure to interferon-γ (IFN-γ) increased casp8 expression and sensitized cells to IR and 
death receptor-mediated cell death [139, 140].  Successful studies using IFN-γ was shown 
in an in vivo Ewing sarcoma xenograft model [139].  A phase I clinical trial using IFN-γ 
to treat NB patients demonstrated that IFN-γ increases casp8 expression.  Combination of 
both IFN-γ and 5-Aza demonstrate significantly enhance casp8 expression and apoptotis 
of cancer cells upon treatment with TRAIL [130].  Retinoic acid (RA) has also been 
shown to induce casp8 transcription via a CREB binding site on the CASP8 gene [127].  
Though inducing casp8 expression may present an attractive therapeutic target, it may 
also promote survival.  Research shows that casp8 expression can be elevated in some 
tumors and some malignant tumors may tolerate high levels of casp8.  Furthermore, 
given the intense selective pressures present in the tumor microenvironment, the 
upregulation of casp8 by demethylating agents may promote these noncanonical 
nonapoptotic prosurvival roles of casp8.  In such situations, increasing casp8 may be 
detrimental [141, 142]. 
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Role of caspase-8 in neuroblastoma 
 
 Interestingly, although casp8 expression is silenced in approximately 50-70% of 
NB patient samples, there are conflicting reports regarding the loss of casp8 in aggressive 
NB.  The most compelling results came from the work performed by Fulda et al. who 
analyzed a total of 162 patient samples.  This study demonstrated that there was no 
significant correlation between the loss of casp8 and MYCN amplification or poor 
prognosis [143].  Results from Takita et al. revealed that 11 of 15 NB cell lines silenced 
casp8 expression, but no correlation was made regarding MYCN amplification [144]. 
 
 To determine the role of casp8 in NB tumorigenesis and metastasis our lab used 
isogenic NB7 cells transduced with physiological levels of casp8, which have genetic 
deletions of both casp8 alleles, and engraftment studies performed in SCID mice injected 
by tail vein (not published).  Interestingly casp8 expressing cells formed more and larger 
tumors in comparison to controls.  In addition, tumor size was also significantly larger in 
casp8 expressing cells.  Paradoxically, casp8 expression in the tumors was decreased.  
These results suggest that casp8 provided some initial benefit for tumor establishment 
though its down-regulation was required in order to survive.  Therefore, casp8 may have 
additional nonapoptotic or noncanonical roles in tumorigenesis, such as increased cell 
adhesion and migration.  Confirmation of the potential role of casp8 in tumor cell 
metastasis was performed by Stupack et al. in collaboration with our lab [145].  The 
chick embryo assay was used to determine the metastatic potential of NB7 cell lines 
seeded onto the chick chorioallantoic membrane (CAM).  These studies revealed no 
significant difference of tumor size between NB7 cells with or without casp8.  NB7 cells, 
absent for casp8 expression exhibited an increased metastatic potential.  In contrast, other 
research groups demonstrated that casp8 expression significantly enhances metastasis and 
may promote tumor growth as previously mentioned [88, 89, 146, 147].  In addition, 
Stupack et al. found that apoptotic cells were located at the tumor periphery in casp8 
positive tumors suggesting that cells expressing casp8 within a foreign environment 
underwent apoptosis [145].  Previous research revealed that casp8 association with 
integrins on the cell surface could mediate a process known as integrin-mediated death 
(IMD).  Therefore, NB7 cells were sorted for high and low integrin expression (α3β1).  
NB7 cells expressing casp8 and integrin at low levels exhibited a higher metastatic rate 
and decreased levels of apoptosis at the tumor periphery.  In contrast, NB7 cells 
expressing physiological levels of casp8 and high levels of integrin did not metastasize 
and underwent apoptosis at a higher frequency.  Tumors from SCID mice and human 
patient samples revealed a decrease in expression level of α3β1 and casp8 suggesting a 
more aggressive phenotype.  Advanced stage NB (stage 3 and 4) showed a decrease in α3 
integrin mRNA [145]. 
 
 In comparison to normal cells, tumor cells are subject to different stressors such 
as hypoxia, radical oxygen species (ROS), starvation, genotoxic insults, and mechanical 
stress.  These stressors promote extracellular matrix (ECM) stiffness, increased survival, 
and integrin activation.  The most common biological results of ECM-cell interaction is 
adhesion, invasiveness, and migration.  This implies that when casp8 levels are low a 
decrease in integrin function may result in cell detachment [148]. 
 14 
 Our lab was the first to demonstrate a role for casp8 in metastasis.  Additional 
research has validated and further clarified casp8 involvement in metastasis [88, 89, 97, 
146, 149].  These experiments were performed using various in vitro matrices; isogenic 
cell lines transduced with physiological levels of casp8, and engraftment studies in 
immunocompromised mice by tail vein and flank injection.  In all studies performed, 
casp8 was validated to have a key role in survival, migration, attachment, and metastatic 
capabilities.  Caspase-8 was also shown to be down-regulated at secondary metastatic 
sites.  In contrast, these results also suggest that the loss of casp8 may promote 
detachment from the primary mass [88, 89, 102, 146, 149]. 
 
 This data suggests that independent of casp8 expression the overall primary tumor 
growth is relatively unaffected.  Caspase-8 expression in the primary tumor may offer a 
selective advantage for cellular invasion and metastasis in that casp8 expression enhances 
cellular attachment and motility.  Paradoxically, expression of casp8 must be silenced in 
order to avoid IMD in the secondary site (Figure 1-6). 
 
 To understand the role of casp8 in NB, Teitz et al tested the in vivo role of casp8.  
To overcome the embryonic lethality of casp8 deficiency in mice, they crossed the TH-
Cre mouse; which expresses the Cre recombinase under the tyrosine hydroxylase (TH) 
promoter at day E9.5, with floxed casp8 mice [83, 150].  Caspase-8 deficiency resulted in 
no tumor formation until these mice were crossed to TH-MYCN mice [151, 152].  As 
previously stated, MYCN amplification occurs in approximately 30% of advance stage 
NB.  Loss of casp8 in mouse neural crest cells with MYCN amplification significantly 
increased bone marrow metastasis; though no significant difference was observed in 
primary tumor growth [152]. 
 
 
Specific Aims 
 
 Caspase-8 is silenced in up to 70% of advanced-stage NB patient tumors and the 
biological consequences of casp8 deficiency results in enhanced metastatic cell survival 
by preventing integrin-mediated cell death and decreased cell sensitivity to 
chemotherapeutic drugs in NB [127, 128, 145, 153].  On the other hand, casp8 expression 
is maintained in 30-50% of NB and promotes ruffle and lamellipodial formation, 
enhanced cell migration, and adhesion [88, 91, 149].  These processes were determined to 
be independent of the enzymatic activity required for apoptosis.  Caspase-8 may also 
regulate cell cycle progression via the S6K pathway, NF-кB activation, and Erk1/2 
activation [86, 87, 96, 101]. Previously, kinases including Src, ATM, p38 MAPK and 
Cdk1 have been shown to modulate and regulate casp8 activity and cellular function via 
phosphorylation.  In general, phosphorylation reduces the enzymatic activity of casp8.  In 
hepatocellular carcinoma and colon cancer elevated levels of phosphorylated casp8 were 
observed, suggesting that the phosphorylation of casp8 may enhance tumorigenesis 
and/or metastasis.  Overall, casp8 appears to be a multi-functional protein playing key 
roles in two opposing processes, cell death and survival.  This phenomenon raises the 
question as to how a single protein can initiate opposing functions within the cell.  The 
studies of this dissertation are designed to examine the hypothesis that casp8 has pro- 
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Figure 1-6. Role of caspase-8 expression levels promote tumorigenesis and 
metastasis. 
Caspase-8 expression within the primary tumor promotes solid tumor formation.  
Continued expression of caspas8 drives tumor growth producing larger tumors than casp8 
deficient tumors.  However, casp8 positive tumors have a larger number of apoptotic 
cells along the tumor periphery.  In vitro studies demonstrate that casp8 positive cells 
have an increased migration and invasive potential.  Tumors located at secondary tumor 
sites have silenced casp8 expression suggesting that casp8 may promote survival at the 
primary tumor site while inducing cell death in foreign microenvironments. 
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death and pro-survival functions during NB tumorigenesis and that post-translational 
modification of casp8 may affect the balance of casp8 between these two opposing 
pathways.  To test this hypothesis, I propose the following specific aims. 
 
 Aim 1:  To determine whether casp8 expression is essential in NB tumorigenesis.  
Approximately, 30-50% of NB patient samples maintain casp8 expression suggesting that 
casp8 may possess noncanonical prosurvival functions.  Studies in this aim will: 
 
a) Examine the biological effect of casp8 expression in NB tumorigenesis. 
 
b) Determine the biological role of the catalytic activity of casp8 in NB 
tumorigenesis. 
 
 Aim 2:  To determine whether the modulation of casp8 by phosphorylation 
promotes critical nonapoptotic functions during NB tumorigenesis.  Previous research 
showed that ATM could phosphorylate casp8 at serine 219 upon ATM activation by 
DNA damaging agents.  Studies in this aim will: 
 
a) Determine if DNA damage induced by irradiation leads to casp8 phosphorylation. 
 
b) Confirm that this modulation of casp8 is dependent on ATM activation. 
 
c) Establish the biological significance of phosphorylated casp8 on apoptotic and 
survival pathways. 
 
d) Identify the effect of casp8 phosphorylation in NB tumorigenesis. 
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CHAPTER 2.    CASPASE-8 PROMOTES NEUROBLASTOMA 
TUMORIGENESIS 
 
 
Introduction 
 
 Neuroblastoma (NB), a childhood cancer of the sympathetic neural crest cells, 
accounts for 7-10% of infant malignancies and 15% of cancer-related deaths in children 
[3, 154].  Advancements in chemotherapies have increased pediatric cancer-survival rates 
to more than 75% while long-term survival rates of patients with advanced-stage NB still 
remain at ~30% [155].  Hallmark genetic abnormalities associated with the poor outcome 
of high-risk NB include MYCN amplification, deletion of 1p, 11q, and gain of 17q [3, 13, 
17, 125, 126].  Defective apoptotic machinery is also commonly associated with 
tumorigenesis and therapeutic resistance [114].  In NB, approximately 50-70% of patient 
tumor samples exhibit a loss of casp8 expression, indicating that casp8 may play an 
important role in tumorigenesis [17].  Other tumors including medulloblastoma, 
retinoblastoma, rhabdomyosarcoma, and small cell lung carcinoma have also been shown 
to silence casp8 expression [118, 119, 121].  Downregulation of casp8 is frequently 
attributed to the hypermethylation of CpG islands within the CASP8 promoter region 
[117]. Research suggests that the loss of casp8 in NB significantly enhanced tumor cell 
metastasis and survival at secondary sites by inhibiting integrin-mediated cell death 
(IMD) [88, 145, 156].  Loss of casp8 in NB decreased cell sensitivity to 
chemotherapeutic drugs [127, 128, 145, 153]. 
 
 Caspase-8, located on chromosome 2q33-34, is the initiator caspase of the 
extrinsic apoptotic signaling pathway [28, 117].  Caspase-8 is composed of a protein-
protein interacting N-terminal domain and a catalytic C-terminal domain; comprised of a 
large and small subunit separated by a short linker sequence [36].  Ligand binding to its 
respective death receptor promotes receptor trimerization and recruitment of the adaptor 
protein, FADD.  The prodomain of casp8, comprised of two death effector domains 
(DED), interacts with the DED domain of FADD.  Recruitment of an additional casp8 to 
FADD allows for casp8 homodimerization; thereby promoting self-cleavage events at 
key aspartic acid residues within the monomers.  These auto-cleavage events relieve 
steric hindrances, increase stability, and induce full activation.  Interestingly, 
dimerization is mandatory for full catalytic activity, not auto-cleavage [54-56, 157].  The 
downstream effects of receptor-mediated casp8 activation is mediated through the 
activation of executioner caspases (caspase-3 and caspase-7) and/or BID cleavage [56, 
63, 158, 159]. 
 
 Caspase-8 has long been considered as primarily a transducer of cell death; 
however, ongoing research has clearly demonstrated casp8 to be a multifunctional and 
multipurpose cellular protein.  Caspase-8 has been reported to be involved in cell 
migration [89, 146, 149], adhesion [88], differentiation [160, 161], proliferation [147, 
162], cell cycle regulation [86], wound healing [98], NF-κB and ERK 1/2 signaling [87, 
94], and Rock activation [97].  Several of these functions are independent of the catalytic 
activity of casp8 and are functionally dependent on specific domains of casp8. 
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 Interestingly, 30-50% of NB patient samples maintain casp8 expression.  This 
phenomenon drives the question as to whether casp8 may be providing a survival 
advantage in this subset of tumor samples, and if so, how is the catalytic activity of casp8 
regulated to promote survival in contrast to cell death.  Prosurvival mechanisms of casp8 
have been shown to promote ruffle and lamellipodial formation, enhanced cell migration, 
and adhesion [88, 91, 149].  In addition, casp8 is linked to cell cycle regulation via the 
S6K pathway, NF-кB activation, and Erk1/2 activation [86, 87, 96, 101].  These 
processes were determined to be independent of the enzymatic activity required for 
apoptosis.  Caspase-8 deficient mice present with severe developmental abnormalities 
leading to death at E10.5, suggesting that casp8 plays a significant role during 
embryogenesis.  The lethality of casp8 knockout can be rescued by rendering casp8 
catalytically inactive by a single point mutation of an essential aspartic acid residue, 
D387 [163].  These results show that casp8 plays a key prosurvival role during normal 
development that is independent of its proteolytic, cell death inducing, property.  
Furthermore, work performed in keratinocytes reveals that casp8 expression is regulated 
during wound healing indicating that casp8 is closely regulated.  Overall, these studies 
demonstrate that casp8 is a multifunctional protein with both proapoptotic and 
prosurvival functions, and in order for cells to survive the enzymatic activity of casp8 
must be controlled. 
 
 Studies performed in fertilized chick eggs revealed that casp8 expression in NB 
cells did not significantly enhance primary tumor growth [145].  This work demonstrated 
for the first time that casp8 may act as a metastasis suppressor gene since data showed 
that cells expressing casp8 were more prone to undergo apoptosis in a foreign 
environment.  Conditional knockout of casp8 in mouse neural crest cells showed similar 
results regarding primary tumor formation and an increase in bone marrow metastasis 
[152].  In contrast, a study comprised of the largest cohort of NB patient samples 
revealed that casp8 is not preferentially lost in advanced stage-NB.  Furthermore, in vitro 
analysis of casp8 shows that casp8 expression enhances metastasis; suggesting a potential 
survival function of casp8 in NB demonstrating why up to half of NB patient samples 
maintain casp8 expression.  Taken together, these studies demonstrate that little is 
understood about the exact mechanism and biological role of casp8 in NB. 
 
 In this study, we hypothesized that casp8 expression is essential in NB 
tumorigenesis.  We examined the role of casp8 to promote cell survival and 
tumorigenesis as determined by our novel orthotopic xenograft model.  For the first time, 
we report that casp8 expression significantly enhanced tumor growth, tumor 
establishment, and decreased overall survival in NB transplanted mice.  Furthermore, we 
demonstrate that the catalytic activity of casp8 is not required for its protumorigenic 
function of primary tumors and that the N-terminal prodomain of casp8 is essential in 
casp8-mediated tumor growth.  We report in our tumor xenografts derived from casp8 
positive cells that casp8 expression is decreased.  A model summarizing our findings is 
proposed that casp8 may be essential for engraftment of our NB cell line in our xenograft 
models.  Increased engraftment promotes tumor growth and development.  At later stages 
of tumor development casp8 is downregulated; thereby, decreasing tumor cell death.  
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Results 
 
 
Caspase-8 expression promotes NB tumor growth in low tumorigenic cells 
 
 To examine the potential biological role of casp8 in NB and explain why casp8 is 
maintained in 30-50% of NB patient samples we employed two isogenic cell lines, NB7 
and NB1691, both deficient for casp8 expression.  Both cell lines were transduced with 
wild-type (wt) casp8 and selected for GFP (green fluorescent protein) positive cells using 
flow cytometry.  Overexpression of casp8 drives cell death; therefore, casp8 was 
expressed at relatively physiological levels.  We compared the reconstituted expression 
levels of casp8 in NB7 and NB1691 cells to four neuroblastoma cell lines expressing 
endogenous casp8 to validate expression levels (Figure 2-1A).  Endogenous casp8 is 
often expressed as two isoforms, represented as a doublet by western blot analysis [164].  
These isoforms only vary by a few amino acids at the N-terminal and have been shown to 
have similar functions and rates in promoting apoptotic cell death [164].  Our NB cell 
lines were reconstituted with the larger 55 kDa isoform of casp8, recognized as the upper 
band.  Densitometric analysis of reconstituted casp8 compared to both isoforms 
supported that casp8 expression is relatively equivalent to endogenous casp8 (data not 
shown).  Cell lines reconstituted with wild-type casp8 will be indicated as C8 (NB7-C8wt 
and NB1691-C8wt) throughout the study. 
 
 Approximately, 40% of NB patient samples develop in the para-adrenal or intra-
adrenal region [7].  To represent this event in a mouse model, we developed a novel, 
minimally invasive, ultrasound-guided orthotopic xenograft mouse model [165].  This 
method results in low morbidity and mortality, and has a high tumor engraftment success 
rate.  Histological examination of xenografts derived from this orthotopic model 
expressed many of the key hallmarks of neuroblastoma including PGP 9.5, 
synaptophysin, neuron specific enolase, and tyrosine hydroxylase [165]. 
 
 To monitor in vivo tumor growth by live imaging, NB7-C8wt and NB1691-C8wt 
cells (GFP positive) were transfected with luciferase and selected for stable expression 
using YFP (yellow fluorescent protein) or zeocin resistance, respectively.  NB cell lines 
with and without casp8 were orthotopically injected into the para-adrenal region of nude 
mice.  NB7 and NB1691 cells expressing empty vectors (NB7-vec or NB1691-vec) were 
used as negative controls.  Tumor growth was monitored weekly by bioluminescence.  
NB7 cells with and without casp8 demonstrated relatively consistent tumor growth until 
week seven.  Between the seven and ten week time points mice reached tumor burden 
and were euthanized in casp8 positive NB7 derived tumors.  A ten week time frame for 
tumor burden is similar to other mouse models; namely tail vein injected xenografts of 
NB7 cells and the TH-MYCN mouse with and without conditional casp8 knockout.  
NB1691 cells with and without casp8 were more tumorigenic and produced tumors as 
early as three weeks, precluding assessment of casp8 in promoting tumor growth in this 
model.  To control for varying expression levels of luciferase in the NB cell lines, 
luminescent values at the weekly time points were normalized to the first week time point 
for each respective mouse.  A two log increase in tumor cell growth from the first week  
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Figure 2-1. Caspase-8 increased neuroblastoma tumorgenicity. 
(A)  NB7 and NB1691 cells were reconstituted with endogenous levels of capase-8 (C8) 
wild-type (wt) and compared to the endogenous levels of casp8 in various NB cell lines.  
(B)  NB cells with and without casp8 (vector control), as indicated, were orthotopically 
injected into the para-adrenal region of nude mice.  Mice were analyzed one week post 
injection to confirm injection and establish a baseline for tumor growth.  Graph 
represents normalized bioluminescent at the 7 week time point. (*, P ≤ 0.005)  (C)  
Survival plot of tumor bearing mice.  Mice with tumors exceeding a two log increase in 
bioluminescence were removed from study. (*, P < 0.001)  (D)  Representative 
bioluminescent images of tumor bearing mice.  Error bars, ± s.e.m. 
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luminescent radiance value was predetermined by experimental data as tumor burden or 
approximately 10% of normal body weight.  NB7 cells with and without casp8 showed 
statistically significant differences by week seven (P < 0.005) and maintained until the 
ten week time point (P < 0.004) (Figure 2-1B).  The more tumorigenic cell line, NB1691, 
demonstrated no significant difference in luminescence between expression of casp8 and 
vector only control (Figure 2-1B).  Comparison of vector controls to casp8wt expressing 
NB7 cells revealed that casp8 significantly increased tumor growth and decreased 
survival from 90% in control cells to 13% by the end of week ten (P < 0.001)        
(Figure 2-1C).  Figure 2-1D is a representative bioluminescent image of mouse 
xenografts derived from both NB cell lines expressing either vector control or casp8 wt.  
Mice were analyzed using the same radiance scale with a range between 1x108 to 5x109 
or 1x107 to 2x108 photons/sec/cm2/sr for NB7 and NB1691 cell lines, respectively 
(Figure 2-1D). 
 
 
Caspase-8 increased tumor engraftment and growth in NB7 cells 
 
 After the ten week time point, mice not having reached tumor burden were 
euthanized and visually analyzed for tumor presence.  All mice enrolled in the study had 
been validated two weeks post injection for successful transplantation by live imaging.  
Interestingly, we observed that NB7 cells lacking casp8 exhibited an orthotopic 
engraftment rate of only 53% (19/36).  On the other hand, casp8 positive NB7 cells 
demonstrated a significantly higher engraftment rate of 96% (21/22) (Figure 2-2A).  
NB7 cells without casp8 maintained luminescent signaling but lacked solid tumor 
establishment, suggesting that the cells were present within the abdominal cavity 
although unable to establish solid tumors.  NB1691 cells, independent of casp8 
expression, were able to establish solid tumors at seemingly similar rates of 67% in 
vector control cells and 76% in casp8 positive cells (Figure 2-2B).  The results presented 
in Figure 2-2 A and B represents only the presence or absence of a solid tumor mass and 
are unbiased based on tumor size.  Since all mice involved in the study were analyzed by 
bioluminescence to confirm successful engraftment prior to study enrollment, this would 
suggest that casp8 expression significantly enhances cell colonization and tumor 
establishment.  Visual analysis of NB7 casp8wt tumors produced significantly larger 
tumors than the casp8 deficient NB7 derived tumors (Figure 2-2C).  Volumetric analysis 
by ultrasound and calipers measurements of tumor size was difficult due to the 
involvement and often the engulfment of the kidney, adrenal, and other possible organs 
by the NB cell lines.  We further noticed that the casp8 positive NB7 tumors were 
seemingly more angiogenic, although histological examination of CD31, an endothelium 
marker, revealed no significant difference between vector controls and casp8 positive 
cells.  The parental NB7 cell line was also tested in our orthotopic model to address 
potential effects contributed by the casp8 expression vector.  After ten weeks, mice were 
euthanized and any visible tumors removed.  Comparison of tumor size between NB7 
parental and vector control lines demonstrated that the tumorigenicity of NB7 cells is not 
affected by the plasmid and is therefore in response to casp8 expression.  In contrast to 
NB7-C8wt cell line, NB7-vec control cells formed small localized tumors easily removed 
from the para-adrenal region, suggesting a proliferative advantage for casp8 positive  
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Figure 2-2. Increased engraftment in caspase-8 positive NB7 cells. 
(A, B)  Following either six weeks or ten weeks, enrolled mice were euthanized and 
analyzed visually for solid tumors.  All mice that were maintained in the study were 
previously determined by bioluminescence to have had successful injections at the one 
and two week time point.  (C, D)  Image of five randomly selected tumors from either 
NB7 parental cell lines, NB7 or NB1691 cells, expressing either vector (vec) only or 
casp8 wild-type (C8wt)  tumor bearing mice.  Scale bar, 1 cm.  (E)  Xenografts of NB7 
cells deficient for caspase-8 (a, c) or reconstituted with wild-type (b, d) were transplanted 
into the para-adrenal region of nude mice and hematoxylin and eosin stained (a, b) or 
stained for phospho-Histone H3 (c, d).  Quantification of positive phospho-Histone H3 
staining from five representative tumors (*, P ˂ 0.05). 
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tumors.  Histological examination of NB7 derived tumors for H&E, CD31, cleaved 
caspase-3, and GFP, showed little difference between vector control and casp8wt tumors 
(Figure 2-2E).  Staining for phospho-Histone H3, a mitotic cell indicator, showed that 
casp8 moderately enhanced tumor cell proliferation (P ˂ 0.05).  Phosphorylation of 
histone H3 promotes DNA condensation, a key step during mitosis.  
Immunohistochemistry of similar markers in tumors derived from the NB1691 tumor 
types showed no significant differences. 
 
 
Loss of caspase-8 affects tumor engraftment 
 
 Our orthotopic xenograft model demonstrated that casp8 promotes primary tumor 
engraftment and growth.  To further validate these findings, we used a common 
metastasis xenograft mouse model whereby cells are injected via tail vein [166].  
Metastasis of cells from the primary tumor involves invasion into the surrounding 
environment, intravasation, extravasation from the blood vessel, and colonization or 
engraftment of the tumor at new sites.  The tail vein model allowed us to investigate the 
possible role of casp8 during the latter stages of metastasis, extravasation and 
colonization of solid tumors.  Therefore, we injected NB7 cells with and without casp8 
via tail vein into severe combined immunodeficiency (SCID)/CB17 female mice.  Mice 
were euthanized nine to ten weeks after injection.  Mouse tumors derived from the casp8-
deficient vector only NB7 cells arising in the adrenal medulla  and ovaries were 
microscopic in size (< 1 mm) in comparison to tumors derived from casp8 positive cells 
(> 1 mm).  Full necropsy on all mice validated NB colonization.  Infiltrated tumor cells 
were identified by H&E and immunohistochemistry (IHC) for the neuronal markers 
synaptophysin and chromogranin A.  Notably, casp8 expression not only markedly 
enhanced tumor establishment in the adrenal medulla, but also in the ovaries, lymph 
nodes, kidneys, liver, lungs, peri-renal fat, and bone marrow, all of which showed no 
infiltration of casp8 deficient NB7 cells.  These results in conjunction with our orthotopic 
studies strongly suggest a positive role for casp8 in primary tumor establishment and 
growth in low tumorigenic cells (Table 2-1). 
 
 
Table 2-1. Loss of caspase-8 affects tumor engraftment. 
 
Tumor Site NB7-vec NB7-C8wt 
Adrenal medulla 0/57* 21/33 
Ovary 0/57** 29/33 
Lymph node 0/57 17/33 
Kidney 0/57 14/33 
Peri-renal fat 0/57 13/33 
Liver 0/57 13/33 
Lung 0/57 4/33 
Bone marrow 0/57 1/33 
Notes: microscopic tumors *37% (21/57), **21% (12/57) 
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Tumorigenesis does not require the proteolytic activity of caspase-8 
 
 Caspase-8 is predominantly known for its canonical role as a catalytic enzyme 
which mediates cell death by the cleavage of various substrates upon activation; however, 
recent studies indicate that casp8 controls several additional functions independent of its 
catalytic property, such as the activation of ERK1/2 by epidermal growth factor (EGF) 
and promoting NF-κB activation [87].  In order to determine whether the catalytic role of 
casp8 is required in NB tumorigenesis, we rendered casp8 enzymatically inactive by site 
directed mutagenesis of cysteine 360 to alanine (C360A).  NB7 cells were stably 
transfected with the C360A casp8 mutant and protein expression levels determined by 
western blot analysis (Figure 2-3A).  To confirm that the point-mutation of C360A 
rendered casp8 catalytically inactive, we exposed our NB7 vector control, casp8wt, and 
casp8 C360A mutant cells to TRAIL [50 ng/mL] and MG132 [1 μM] for 24 hours and 
then blotted for casp8 cleavage and downstream cleavage events of active casp8     
(Figure 2-3B).  MG132 is a potent proteasome inhibitor that sensitizes NB7 cells to 
death receptor-mediated apoptosis.  We demonstrated that casp8 C360A activity was 
significantly compromised as previously reported [73, 76, 167].  Investigation as to 
whether the catalytic activity was required for xenograft engraftment and tumor growth, 
NB7 casp8 C360A cells were orthotopically injected into CD1 nude mice.  Mice were 
analyzed as previously described.  Briefly, mice were monitored weekly for 
bioluminescence and radiance measured.  A two log increase in tumor bioluminescence 
was predetermined as tumor burden, as previously described.  Mice were sacrificed at 
tumor burden or at the end of the ten week study.  Bioluminescent imaging revealed that 
tumors derived from the NB7 casp8 C360A cell line grew moderately faster by seven 
weeks (P ≤ 0.05), as compared to the NB7 casp8wt xenografts (Figure 2-3C).  For 
comparison, NB7 vector control and NB7 casp8wt data is presented from Figure 2-1.  
Overall, this data suggests that the catalytic activity of casp8 may hinder tumor growth.  
This conclusion supports previous research by others demonstrating that the catalytic 
activity is not required for cell survival [87, 91, 92].  Survival of mice transplanted with 
NB cells expressing casp8wt and catalytically inactive casp8 are essentially equivalent at 
10 weeks (~15%); however, mice bearing casp8 C360A NB tumors have a higher 
mortality rate compared to those with NB casp8wt tumors starting at seven weeks 
(Figure 2-3D).  By ten weeks, most mice enrolled in the NB7-casp8 C360A study had 
been euthanized due to tumor burden.  Figure 2-3E is a representative bioluminescent 
image of mice bearing tumors deriving from NB7 vector control, casp8wt, or casp8 
C360A cell lines at seven weeks post injection set to a scale of 1x108 to 5x109 radiance 
(Figure 2-3E).  These data demonstrate that the catalytic activity of casp8 suppresses 
tumor growth and promotes cell survival.  Furthermore, these findings support the 
hypothesis that the regulation of the canonical proteolytic and apoptotic function of casp8 
may foster a more noncanonical prosurvival activity. 
 
 
Catalytically inactivated caspase-8 did not enhance tumor engraftment 
 
 Ten weeks after orthotopic injection, mice enrolled in the NB7 casp8 C360A 
study not having reaching tumor burden were euthanized and visually inspected for the  
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Figure 2-3. Catalytic activity of casp8 suppressed tumor growth. 
(A)  Expression of casp8wt (C8wt) and the catalytically inactive casp8 (C360A) in NB7 
cells.  (B)  NB7 cells expressing both casp8wt and the mutant caspase-8 were treated with 
TRAIL [50 ng/mL] and MG132 [1 μM] for 24 hours and analyzed for casp8 activation 
and casp8-mediated signaling (n.s., not specific)  (C)  NB7 cells expressing vector (vec) 
only, C8wt, or the C360A mutant casp8, were orthotopically injected into the para-
adrenal region of nude mice.  Graph represents normalized bioluminescence at the seven 
week time point (*, P ≤ 0.05, ** P ≤ 0.03).  (D)  Survival plot of tumor bearing mice.  
Mice demonstrating a two log increase in bioluminescence were removed from the study 
(*, P ˂ 0.0001).  (E)  Representative bioluminescent images of tumor bearing mice.  
NB7-vec and C8wt data was shown previously and is only shown for comparative 
purposes.  Error bars, ± s.e.m. 
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presence of a solid tumor mass.  Engraftment rates were calculated based on the total of 
mice in the study and the number of mice presenting with solid tumors after ten weeks.  
These results were unbiased in regard to tumor size.  NB7 casp8 C360A cells 
demonstrated a 96% engraftment rate which was identical to NB7 casp8wt cells    
(Figure 2-4A).  Interestingly, the inactivation of casp8 enhances tumor growth; though 
has no obvious effect on tumor engraftment.  These data imply that casp8 may modulate 
various signaling pathways during tumorigenesis based on its catalytic activity affecting 
proliferation and colonization.  As previously stated, all mice, prior to enrollment into the 
study were analyzed by bioluminescence weekly and luminescent signal was required to 
be maintained for at least two weeks post injection.  Accurate tumor volume was difficult 
to obtain due to the involvement and engulfment of regional organs.  Therefore, we 
randomly selected five tumors derived from the indicated cell lines as a visual 
representation of tumors extracted from mice (Figure 2-4B).  Visually we noticed no 
significant size differences between NB7 casp8wt and NB7 casp8 C360A tumor masses.  
Analysis of phosphorylated Histone H3 in positive cells showed that casp8 C360A 
tumors were similar in proliferation compared to casp8wt expressing tumors and more 
than NB7 vector control tumors (Figure 2-4C). 
 
 
The protumorigenic function of caspase-8 is dependent on the prodomain 
 
 Caspase-8 contains multiple domains that may have unique and specific functions 
independent of its proapoptotic function.  The DED domain of casp8 is crucial for the 
activation of ERK1/2 by epidermal growth factor (EGF) independent of the proteolytic 
activity of casp8 [87].  The DED domain of casp8 also has been shown to induce NF-κB 
activation and bind to perinuclear microtubules during paclitaxel-mediated apoptosis and 
during differentiation of skin and myeloid cells [92, 111, 112].  To determine the 
contribution of the DED in tumorigenesis, truncated casp8 (deleted amino acids 210-479) 
comprising the large and small subunits of the catalytic domain (CD) was stably 
expressed in NB7 cells (NB7-casp8 CD) (Figure 2-5A).  Protein expression of casp8 CD 
was determined by western blot analysis (Figure 2-5B).  NB7 casp8 CD cells were then 
orthotopically injected into nude mice following the procedures as described in the 
Materials and Methods section (Chapter 2).  Mice were analyzed weekly for 
bioluminescence, mice lacking or losing luminescent signal before the two week time 
point were removed from the study.  At seven weeks post injection, NB7 casp8 CD 
derived xenografts expressed bioluminescence at a statistically higher level compared to 
NB7 vector control xenografts (Figure 2-5C).  At seven weeks there was no statistically 
significant difference between NB7 casp8wt and NB7 casp8 CD xenografts.  
Surprisingly, we noticed at time points eight, nine, and ten weeks that the luminescent 
signal for NB7 casp8 CD cells remained relatively consistent showing little to no tumor 
growth.  We then compared the overall survival rates of NB7 casp8 CD cells to NB7 
vector control and casp8wt xenografts (Figure 2-5D).  NB7 casp8 CD xenografts 
demonstrated a slightly lower survival rate from the control NB7 vector control 
xenografts.  An increase in overall survival supports our bioluminescence data 
demonstrating that NB7 casp8 CD xenografts do not grow as rapidly as NB7 casp8wt 
xenografts.  NB7 casp8 CD cells demonstrated a 72% survival rate while NB7 vector  
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Figure 2-4. Inactivated of caspase-8 did not enhance tumor engraftment. 
(A)  Images of tumors randomly selected from the indicated NB7 cell line.  Scale bar, 1 
cm.  (B)  After 10 weeks, mice enrolled in the study which had not reach tumor burden 
were euthanized and analyzed visually for solid tumor engraftment.  NB7-vec and C8wt 
data was previously shown.  (C)  Quantification of positive phospho-Histone H3 staining 
from five representative tumors (*, P ≤ 0.05). 
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Figure 2-5. The prodomain is essential for caspase-8 tumorgenicity. 
(A)  A cartoon representation of casp8 depicting the truncated construct of casp8 
comprising of catalytic domain from residue 210-479. (B)  Protein expression levels of 
the truncated form of casp8 CD (C8 CD) compared to casp8wt (C8wt) NB7 cells.  (C)  
NB7 cells expressing vector (vec) only, casp8wt, or truncated casp8 were orthotopically 
injected into the para-adrenal region of nude mice.  Graph represents normalized 
bioluminescence at the seven week time point (*, P ˂ 0.005).  (D)  Survival plot of tumor 
bearing mice.  Mice with tumors exceeding a two log increase in bioluminescence were 
removed from study.  (E)  Representative bioluminescent images of tumor bearing mice.  
NB7-vec and C8 data was previously shown.  Error bars, ± s.e.m. 
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control and casp8wt cells had overall survival of 90% and 13%, respectively.          
Figure 2-5E is a representative bioluminescent image of NB7 vector control, casp8wt, 
and casp8 CD cells at time point seven weeks.  Radiance scale was set with a minimum 
of 1x108 to a maximum of 5x109 radiance.  All NB7 vector only and NB7 casp8wt data 
was previously detailed in Figure 2-1 and is shown here for comparative purposes. 
 
 
Lack of the N-terminal prodomain suppresses tumor growth 
 
 To determine whether NB7 casp8 CD cells were able to establish solid tumors in 
the para-adrenal region, transplanted mice were euthanized at the ten week time point and 
subjected to detail pathological review.  Notably, NB7 casp8 CD cells demonstrated a 
reduced tumor establishment rate (72%) compared NB7 casp8wt cells (95%)         
(Figure 2-6A).  Furthermore, NB7 casp8 CD tumors were slightly larger than the NB7 
vector control xenografts, but markedly smaller than NB7 casp8wt tumors.  Quantitative 
analysis of tumor size was unattainable due to the difficulty of obtaining accurate 
measurements since tumors often involved other organs.  Probing for phospho-Histone 
H3 positive cells showed that casp8 CD tumors were significantly less proliferative 
compared to casp8wt expressing tumors (Figure 2-6C). These findings are consistent 
with the prolonged survival rate of mice bearing NB7 casp8 CD xenografts compared to 
animals harboring NB7 casp8wt tumors (Figure 2-5D). 
 
 
Overall expression of caspase-8 is diminished in orthotopic xenografts 
 
 Previous data suggests that primary tumor formation is unaffected by casp8 
expression; however, in secondary metastatic tumors, casp8 expression is seemingly 
selected against [145].  We sought to determine if in our orthotopic xenograft model if 
casp8 expression is maintained.  Therefore, we performed western blot analysis on 
tumors derived from NB7 cells expressing casp8 wt.  NB7 vector only, and casp8 
parental cell lines were used as our negative and positive control, respectively       
(Figure 2-7A).  Each well contains 30 μg of total protein lysate.  To lessen the possibility 
of contaminating mouse cells in our lysate and affecting total human protein 
concentration, we quantified casp8 expression levels by densitometric analysis 
normalized to the individual GFP expression and compared to casp8/GFP parental cell 
line.  Densitometric analysis revealed that only 20% of NB7 casp8wt expressing cells 
maintained relatively similar levels of casp8 (Figure 2-7B).  RT-PCR analysis 
demonstrated that approximately 25% of NB7 casp8wt tumors suppressed casp8 at the 
transcript level while the remaining 75% seemingly regulated casp8 at either the 
translational or posttranslational level (Figure 2-7C).  Furthermore, casp8 expression in 
NB7 casp8 C360A tumors had a decrease in overall casp8 expression similar to casp8wt 
xenografts; however, NB7 casp8 CD maintained expression of the catalytic domain 
(Figure 2-8A).  Caspase-8 lacking the DED domains essentially rendered casp8 
enzymatically inactive and posed no known apoptotic threat; which may explain why the 
maintenance of casp8 CD expression in xenografts.  These findings may suggest that 
casp8 may promote cell survival signaling during the initial or early stages of  
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Figure 2-6. The N-terminal prodomain is required for tumor growth. 
(A)  Randomly selected orthotopic xenografts from the indicated NB7 cell lines.  Scale 
bar, 1 cm.  (B)  After ten weeks, mice were analyzed visually for solid tumor 
engraftment.  Comparison of NB7 cells with and without casp8wt was shown previously.  
(C)  Quantification of positive phospho-Histone H3 staining from five representative 
tumors (*, P ˂ 0.01). 
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Figure 2-7. Caspase-8 is diminished in orthotopic xenografts. 
(A)  Caspase-8 expression in tumor xenografts derived from NB7 cells expressing 
casp8wt.  Control lanes consist of parental cell lines reconstituted with either vector only 
or indicated casp8 construct.  (B)  Caspase-8 expression levels, as determined by western 
blot, were analyzed by densitometry for casp8 expression and normalized to the 
representative GFP expression level and compared to control cell line. (C)  Relative 
expression of casp8 mRNA normalized to ubiquitin.  Xenograft numbers are the same for 
each experiment.  Error bars, ± s.d. 
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tumorigenesis.  NB1691 vector and casp8wt cells were also analyzed for casp8 
expression revealing that casp8 is lost at three to six weeks post-injection (Figure 2-8B). 
 
 
Discussion 
 
 Caspase-8 is shown to be silenced in up to 70% of NB, 52% of medulloblastoma, 
and 79% of single cell lung carcinoma (SCLC) (79%) [120, 122, 131, 143, 168, 169].  
Loss of casp8 in tumors is shown to promote metastasis by suppressing IMD and 
decrease cell sensitivity to death promoting chemotherapeutic agents [127, 145, 156].  
Taken together, these results support the notion that the loss of casp8 protects cells from 
apoptotic cell death and may promote tumorigenesis.  Paradoxically casp8 has been 
shown to have very opposing functions within the cell.  For example, casp8 increased cell 
adhesion in tissue culture models and migration [88, 89, 145, 146, 149].  Caspase-8 
expression is shown to be required for mouse embryogenesis for normal vasculature, 
heart, and neural tube formation [82].  Approximately 30-50% of NB patient samples 
maintain casp8 expression.  These data support on-going research demonstrating that 
casp8 not only has proapoptotic but prosurvival functions, independent of the enzymatic 
activity of casp8. 
 
 Most commonly in NB as well as other cancers, casp8 repression is a result of 
hypermethylation at CpG islands within the CASP8 promoter region [117, 121, 123].  
Methylation of the promoter region regulates casp8 expression thus allowing, based on 
cellular conditions and signaling, for casp8 re-expression.  During the wound healing 
process casp8 expression is silenced at sites proximal to the wound, though restored after 
the healing process demonstrating the possibility that casp8 is closely controlled and 
regulated [98].  This suggests that casp8 may be expressed and silenced based on 
environmental signaling, stressors, and/or signaling events.  Therefore, based on these 
data demonstrating that casp8 has prosurvival functions and may be regulated during 
tumorigenesis, we set out to test whether casp8 expression enhances NB tumorigenesis. 
 
 To investigate the potential biological role of casp8 in tumorigenesis, we 
developed a novel ultrasound guided orthotopic xenograft mouse model, which allowed 
us to inject our cells into the para-adrenal space of immunocompromised mice.  We then 
selected two NB cell lines based on their tumorigenicity.  Preliminary data suggested that 
the NB7 cell line is less tumorigenic in comparison to the NB1691 cell line.  NB cell 
lines were stably transfected with casp8wt and validated for stable expression         
(Figure 2-1A).  Endogenous casp8 is commonly expressed as a doublet represented by 
two different isoforms of casp8 known as caspase-8/a and caspase-8/b.  Biologically, no 
significant difference was observed between the two isoforms.  Kinetics and protein-
protein interactions were similar between the isoforms.  Caspase-8/a is slightly smaller 
due to the lack of approximately 15 amino acids from the N-terminal region.  Due to an 
extension of the N-terminal region from the DED domains, this lack of amino acids does 
not affect the DED domains of casp8 [164].  NB cell lines were reconstituted with the 
caspase-8/b isoform.  Densitometry analysis of exogenous casp8 protein level was 
compared to both isoforms as a whole, since both isoforms were functionally similar, and  
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Figure 2-8. Overall expression of caspase-8 is diminished in orthotopic 
xenografts. 
(A, B)  Western blot analysis of casp8 expression in tumor xenografts derived from 
NB7/NB1691 vector control, casp8wt, and NB7 cells expressing either catalytically 
inactive casp8 (C360A) or truncated casp8 (catalytic domain only).  Control lanes consist 
of parental cell lines reconstituted with either vector only or indicated casp8 construct.  
(C)  Densitometry analysis of xenograft casp8 expression compared to control cell line 
Error bars, ± s.e.m. 
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confirmed that casp8 was reconstituted at relative physiological levels (data not shown).  
Surprisingly, NB7 tumorigenicity was significantly enhanced by casp8 expression, yet 
NB1691 with and without casp8 showed similar tumor growth.  In previous studies, 
NB1691 cells were more tumorigenic than NB7 cells suggesting the possibility that 
genetically the NB1691 cells may have acquired additional mutations allowing for 
advanced tumor growth.  Therefore, their requirement for casp8-mediated tumorigenicity 
was secondary and overall unnecessary.  Based on this assumption, NB1691 cells are not 
informative to investigate tumorigenesis driven by casp8.  Therefore, expanding our 
studies to involve other low tumorigenic casp8 deficient cell lines, such as NB10 and 
NB8, provide additional opportunities to challenge the role of casp8in promoting 
tumorigenesis.  In addition, previous tumor growth studies demonstrate that NB10 and 
NB8 both have similar xenograft tumor growth rates as NB7 cells. 
 
 Previous studies performed in the chick chorioallantoic membrane (CAM) assay 
demonstrated that casp8 had no significant effect on tumor growth [145].  The CAM 
assay is extremely sensitive and often times overly sensitive, inducing an inflammatory 
and angiogenic response to an irritant [170, 171].  The CAM assay has been extremely 
valuable for the analysis of angiogenesis and metastasis; though not commonly used for 
tumor growth studies and comparisons.  Our orthotopic xenograft model implicating a 
role for casp8 in promoting tumorigenesis was previously tested and validated to 
effectively mimic the expression of key hallmarks of the TH-MYCN mouse model and 
NB patient tumor samples [165].  No such studies have been published for NB tumor 
growth in the CAM assay.  NB7 cells with and without casp8, were seeded on the 
chorioallantoic membrane of fertilized chick eggs at a concentration of 5x106 cells per 
egg and tumors were harvested seven days later.  In comparison, our orthotopic mouse 
model required 2x105 cells per mouse and up to ten weeks for tumor burden.  The time 
frame of the orthotopic model closely mimics that of the transgenic TH-MYC mouse 
model and other xenograft mouse models using NB cells.  Over seeding of NB cells may 
decrease selective advantages and obscure key cellular mechanisms when exposed to 
environmental pressures.  This may have played a role in our inability to observe a 
difference in our NB1691 cells with and without casp8.  Therefore, additional research is 
required to reassess NB1691cell number in our orthotopic mouse model. 
 
 The NB cell lines were reconstituted with two independent vectors expressing 
either casp8 and GFP or luciferase and YFP.  To confirm that our vectors were not 
inadvertently impacting tumorigenicity, we orthotopically injected our parental NB7 cell 
lines lacking all vectors and constructs, into the para-adrenal region of nude mice.  These 
cells were not manipulated in any form, which precluded the monitoring of tumor growth 
during the ten week study.  After ten weeks, the tumors derived from the parental cell 
lines were visually compared to NB7 vector control and casp8wt expressing cells and 
noted to be significantly smaller than casp8wt, but very similar to vector control cells.  
Our data suggests that our vectors and our method of selecting for vector positive cells 
did not artificially select for a less tumorigenic cell colony or transform the cells   
(Figure 2-2C).  Furthermore, we injected our NB7 cells with and without casp8 into the 
flank of nude mice at the same cell concentration as our orthotopic model.  Mouse flank 
tumors were analyzed weekly by bioluminescence for ten weeks.  Tumor growth of the 
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flank injected NB cells were similar to the para-adrenal xenografts, but did not reach 
tumor burden (Figure A-3C).  These findings suggest that NB cells interacted similarly 
in both sites, but respond differently to environmental signaling and growth factors.  
Overall, casp8 enhanced NB tumorigenesis whether in the para-adrenal region or flank. 
 
 Visual analysis of our orthotopic xenografts suggested an increased level of 
vascularization in casp8 positive NB7 cells.  Support for this observation derives from the 
casp8 knockout mouse which is embryonic lethal due to decreased vasculature as well as 
heart and neural tube defects [82].  An increase in angiogenesis may also explain why we 
observed an increase in tumor growth in NB cells expressing casp8wt.  Histological 
examination of CD31 did not demonstrate a quantitative difference between NB7 cells 
with or without casp8.  The conflict between our visual analysis and 
immunohistochemistry may be due to a small sampling size.  Additional studies would 
include a larger sample number and include probing for additional endothelial and 
angiogenesis markers such as CD34, CD105, platelet endothelial cell adhesion molecule 
(PECAM-1), von Willebrand factor (vWf), and vascular endothelial growth factor 
(VEGF) will be necessary to address the potential role of NB in angiogenesis and 
consequently tumorigenesis. 
 
 To our knowledge, this is the first report demonstrating that casp8 may promote 
primary tumor formation and growth in NB cells.  Confirmation of the protumorigenic 
potential of casp8 was performed by tail vein injection of NB7 vector and casp8wt cell 
lines.  Analysis of tumorigenesis using the tail vein xenograft model specifically targets a 
cell’s ability to extravasate from the blood vessel and colonize in a foreign environment.  
Our data demonstrates that casp8 positive cells significantly enhanced cellular 
extravasation, colonization within a foreign environment, and increased tumor formation 
in an increased number of foreign sites (Table 2-1).  These results were confirmed by full 
necropsy, immunohistochemistry, and immunoblot analysis.  This data supports data 
from our orthotopic xenograft model, as well as, that of previously published research 
demonstrating that casp8 enhances metastasis, in vitro [88, 91, 149].  Extravasation from 
the vasculature and migration into a foreign environment are stages of the metastatic 
process, both of which casp8 expression has been shown to enhance, in vitro. 
 
 Previous research demonstrated that casp8 enhances cell adhesion, invasion, and 
metastasis which supports our two xenograft models, orthotopic and tail vein, 
demonstrating a striking advantage to casp8 expression in NB tumorigenesis [88, 89, 146, 
149].  In contrast, studies conducted in TH-MYC transgenic mice that that are 
conditionally deficient in casp8 within the neural crest lineage demonstrate that casp8 
limits NB tumorigenesis.  Although loss of casp8 in this genetically engineered mouse 
model enhanced bone marrow metastasis, there was no difference in primary tumor 
formation with or without casp8 [152].  Unfortunately, this mouse model only represents 
approximately 30% of advanced-stage NB (stages 3-4) of which casp8 silencing is still 
controversial in this setting [17, 143, 144].  Furthermore, rarely is casp8 deleted in NB 
and is more commonly suppressed; thereby suggesting a mode of regulation and possible 
re-expression, as opposed to complete abolishment.  Taken together with our xenograft 
data, casp8 may be essential not only in the initial primary tumor growth but during 
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metastasis as well.  In order to fully characterize the role of casp8 in NB tumorigenesis 
additional research exploiting both the conditional casp8 knockout mouse model as well 
as xenograft models will be required. 
 
 The prosurvival functions of casp8 may not be dependent on the catalytic activity 
or domain.  For example, the DED domains of casp8 initiated ERK1/2 activation when 
exposed to EGF while studies showed that the catalytically inactive casp8 promoted NF-
κB signaling [87, 93, 94].  Point-mutation of casp8 at a critical aspartic acid residue 
rendered casp8 catalytically inactive and rescued the embryonically lethality of casp8 
knockout mice.  This suggests that the developmental functions of casp8 may not be 
dependent on its enzymatic property.  To investigate the functionality of the enzymatic 
property of casp8 in promoting NB tumorigenesis, we mutated casp8 at the catalytic 
cysteine 360; thereby rendering casp8 enzymatically inactive.  Injection of our NB7 
casp8 C360A cells into the para-adrenal region of immunocompromised mice 
demonstrated an increase in tumorigenesis as indicated by enhanced tumor growth by 
seven weeks and a decrease in overall survival from seven to nine weeks when compared 
to NB7 casp8wt derived tumors.  Interestingly, independent of the catalytic activity of 
casp8, the overall survival of tumor bearing mice was 13% after ten weeks.  Mice 
transplanted with cells expressing the catalytically inactive casp8 developed more 
pronounced tumors earlier indicated by more than a 20% decrease in survival at seven, 
eight, and nine weeks.  Increasing our sample number and inclusion of earlier time points 
(five and six weeks) may more clearly define differences between the two casp8 
constructs.  Tumor engraftment, however, was not affected by the casp8 catalytic activity.  
Interestingly, by ten weeks the overall survival of NB7 casp8wt cells was comparable to 
NB7 casp8 C360A tumors suggesting that the enzymatic activity of casp8 slowed the 
tumorigenicity of NB7 casp8wt cells.  These results imply that the catalytic activity of 
casp8 hinders NB onset and that during NB tumorigenesis it is advantageous for NB cells 
to suppress the enzymatic activity of casp8.  Furthermore, casp8wt enhances overall 
tumor growth and establishment yet inactivation of casp8 promotes tumor growth and not 
establishment.  This would suggest that casp8 may have more than one signaling function 
based on its enzymatic activity during NB tumorigenesis; which affects both proliferation 
and colonization.  In contrast, NB7 cells expressing only the catalytic domain of casp8 
(NB7 casp8 CD) demonstrated an increased survival from 13% in NB7 casp8wt derived 
tumors to 72%.  There was no statistical difference between NB7 vector and casp8 CD 
xenografts in overall survival; however, there was significant difference between casp8wt 
and the truncated mutant (P ˂ 0.001).  Visual analysis of NB7 casp8 CD tumors clearly 
demonstrate a lack of tumor growth in comparison to NB7 casp8wt tumors and more 
closely resemble NB7 vector tumors.  Truncation of casp8 maintained similar tumor 
engraftment rates as NB7 casp8wt tumors.  This implies that during the various stages of 
tumorigenesis namely, colonization (i.e. engraftment) and primary tumor growth, casp8 
may promote functions independent of its proteolytic activity and be domain specific.  
We propose that the catalytic domain is essential in the establishment of NB7 tumors 
demonstrating that binding to an adaptor protein, such as FADD or TRADD, is not 
required.  Tumor growth may be enhanced by binding to the adaptor proteins, suggesting 
that two possible signaling pathways of casp8 may influence NB tumorigenesis.  
Furthermore, our data suggests that the enzymatic activity hinders tumor growth implying 
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the possibility that the catalytic activity of casp8 during NB tumorigenesis is tightly 
controlled and/or regulated, possibly explaining why up to 70% of NB patient samples 
silence casp8 expression by methylation as opposed to deletion. 
 
 Previous research suggested that during tumorigenesis casp8 positive cells are 
selected against since casp8 deficient cells are protected against IMD [145].  Western blot 
analysis of our NB7 vector, casp8wt, casp8 C360A, and CD tumors revealed that overall 
casp8 expression is lost as indicated by densitometric analysis.  Closer examination of 
casp8 expression on an individual tumor basis demonstrates that several tumors maintain 
basal levels of casp8 expression.  Maintenance of casp8 expression may be tumor region 
specific or maintained for cell survival purposes.  Since there is a lack of casp8 antibodies 
that are useful for immunohistochemical analyses, we could not confirm if casp8 was 
expressed more prominently in some regions than others in the tumor.  Analysis of casp8 
mRNA expression suggests that casp8 may be regulated by posttranslational regulatory 
methods, in this model.  Similarly, we found no detectable expression of casp8 in our 
western blot analysis of tumors derived from NB1691 casp8wt cells.  Additional research 
involving the regulation of casp8 protein expression in NB at early and late stage 
tumorigenesis is warranted. This important issue may be addressed by establishing tumor 
explants or cell line cultures short term in vitro and casp8 expression monitored by pulse-
chase analysis with and without proteasomal inhibitors. 
 
 Overall, this data supports previous literature demonstrating that casp8 is a 
multifunctional protein independent of its proteolytic activity and domain.  For the first 
time, these studies demonstrate a protumorigenic function of casp8 as determined by an 
increased in tumor cell engraftment and proliferation in casp8 positive NB7 cells.  These 
results were shown to be independent of the catalytic activity.  Further research is 
required in order to elucidate the exact mechanisms of casp8 during NB tumorigenesis.  
We propose time course studies involving the extraction of primary tumor masses at 
specific stages post orthotopic injection into nude mice.  These tumors would be 
monitored by ultrasound for tumor volume and by bioluminescence.  Protein levels 
would be determined by western blot analysis and protein transcript levels by RT-PCR.  
Level of casp8 regulation in our xenograft models would include polysomal preps and 
pulse-chase experiments.  Visual analysis of our tumors suggested that casp8 positive 
NB7 xenografts had a higher level of vasculature.  To investigate the possibility of casp8 
in NB angiogenesis, we suggest probing our xenografts with additional markers of 
angiogeneisis such as CD34, CD105, and VEGF. 
 
 The next critical aspect of characterizing the function of casp8 in tumorigenesis is 
to elucidate the mechanism and signaling pathways induced by casp8.  Mechanistically, 
casp8 has been shown to have a higher affinity for FLIP heterodimerization as opposed to 
homodimerization with casp8.  It has been suggested that casp8 homodimerization 
transduces apoptosis while heterodimerization mediates cell survival, due to FLIP 
inability to induce the intersubunit cleavage events of casp8.  Caspase-8 involvement 
with integrins has shown to promote ERK1/2 signaling and metastasis.  Therefore, 
priority will be given in determining if casp8 heterodimerizes with FLIP or associates 
with integrins.  To perform such experiments, casp8 will be tagged using His or FLAG in 
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order to perform coimmunoprecipitation experiments from cells and xenografts.  Controls 
will be conducted using bead only immunoprecipitations to determine non-specific 
binding. 
 
 
Materials and Methods 
 
 
Cell lines 
 
 Human neuroblastoma, NB7 and NB1691 cell lines have been previously 
described [17, 128].  Briefly, neuroblastoma cell lines were established by St. Jude 
Children’s Research Hospital.  All NB cell lines including were maintained in RPMI 
1640 supplemented with 10% FBS, 1% glutamine and 0.1% gentamicin (Invitrogen, 
Grand Island, NY).  All cells were maintained in a humidified atmosphere of 5% CO2 at 
37oC.  NB7 and NB1691 cell lines were reconstituted with casp8 using the 
pMSCV_IRES_GFP retroviral vector.  Retrovirus supernatants were prepared as 
previously described [17, 172].  Briefly, NB cells were cultured with viral supernatants 
plus polybrene [4 μg/ml].  Viral supernatant was replaced with fresh supernatant every 2 
hrs for 6 total hours.  Infections were allowed to occur for a total of 72 hours at 37oC.  
After 72 hours, cells were sorted for GFP expression.  Collected cells were cultured for 
two weeks prior to being sorted again for GFP expression.  Luciferase expression in NB7 
cells was accomplished using the pMSCV_Luc_IYFP construct packaged in the 
previously described retroviral transduction method.  For NB1691 cells, 3x106 cells were 
electroporated at 200 volts with 30 μg of the pMSCV-LucSh-zeocin construct and 
selected for zeocin resistance [100 μg/mL]. 
 
 
Reagents 
 
 Mouse anti-casp8 (C15) was a gift from Dr. M. Peter [158].  Goat anti-actin (C-
11), was obtained from Santa Cruz Biotechnology, anti-rabbit GFP (A-11122) was from 
Invitrogen, anti-rabbit BID (2002) and cleaved casp8 (D391) were from Cell Signaling.  
rabbit anti-phospho-BID (S78) (A300-528A) from Bethyl Laboratories. All antibodies 
were used as recommended by manufacturer.  Caspase-8 mutations were developed by 
the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) and 
manufacturer’s recommendations followed.  Mouse trueblot was purchased from 
Rockland Scientific (18-8817-33). 
 
 
Immunoblotting 
 
 Cells were lysed in Nonidet P-40 lysis buffer (20 mM Tris (pH 7.5), 150 mM 
NaCl, 1 mM EDTA, and 0.5% Nonidet P-40) plus 1 mM PMSF, protease inhibitor 
cocktail (Roche, Mannheim, Germany) and phosphatase inhibitors (1 mM NaF, 1 mM 
Na3VO4, and 1 mM beta-glycerophosphate) for 5 minutes on ice followed by sonication.  
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Lysates were centrifuged at 14,000 rpm for 10 minutes.  Supernatants were removed and 
total protein was quantified using the Bradford assay (Bio-Rad, Hercules, CA).  Proteins 
(30 μg) were separated using SDS-PAGE analysis.  Immunoblots were visualized using 
unlabeled primary antibodies and HRP-conjugated secondary antibodies.  Protein 
expression was detected using enhanced chemiluminescence from GE Healthcare 
(Pittsburgh, PA).  Quantification of band intensity was performed using the NIH ImageJ 
program. 
 
 Tumor samples were minced using a clean razor blade and suspended in ACK 
buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) for 1 minute on ice to lyse RBC 
and repeated in needed.  Tumors were subsequently washed with PBS and suspended in 
RIPA buffer (150 mM NaCl, 50 mM Tris (pH 8.0), 0.5% sodium deoxycholate, 0.1% 
SDS, 1% NP-40) plus protease inhibitor (Roche, Mannehim, Germany).  Tumor samples 
were maintained in RIPA buffer for 5 minutes on ice and sonicated until tumor dissolved.  
Protein concentration was determined using the Bradford assay (Bio-Rad, Hercules, CA).  
Proteins (30 ug) were separated using SDS-PAGE. 
 
 For immunoprecipitations, cells were lysed in Nonidet P-40 lysis solution 1 hour 
after exposure to either 10 Gy of irradiation using a 137Cs source (Gammacell40-
extractor, MDS Norton) or 75 J/m2 by a UV Strataliner 2400 (Stratagene).  Caspase-8 
was pulled-down from 1 mg of cell lysate using the C15 caspase-8 antibody bound to 
protein G agarose beads (Pierce # 20398) or cross-linked to A/G agarose beads using a 
Pierce cross-linking kit (cat#26147, Rockford, IL) and eluted from beads according to 
manufacture recommendation.  Protein G agarose beads were washed in Nonidet P-40 
lysis solution three times and suspended in SDS sampling buffer and boiled for 10 
minutes. 
 
 
MTT 
 
 Cells were cultured in 96 well plates under indicated conditions.  At various time 
points, spent medium was removed and replaced with 20 ul phenol red-free RPMI 1640 
containing 5% FBS and 0.5 mg/mL MTT for 3 hours at 37oC.  Isopropanol (200ul) was 
added to dissolve the MTT formazan crystals.  Absorbance was measured at 570 nm and 
background at 690 nm. 
 
 
Orthotopic xenograft 
 
 Ultrasound-guided orthotopic xenograft procedures were previously detailed 
[154].  Briefly, cells were suspended in Matrigel (BD worldwide, Cat#354234, San Jose, 
CA) at a concentration of 2x104 cells/μL and kept on ice.  Using a VisualSonics VEVO-
770 High Frequency Ultrasound system (VisualSonics, Toronto, Canada), a 22 gauge 
catheter was inserted into the para-adrenal space through the back muscle of anesthetized 
CD1 nude mice.  A Hamilton syringe loaded with 10 μL of cell suspension was guided 
steriotactically into the region between the kidney and adrenal gland and injected.  For 
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tumor growth analysis, mice were injected (intraperitoneal) with 3 mg/mouse of Firefly 
D-Luciferin (Caliper Life Sciences) and imaged using the IVIS® 200 imaging system.  
Bioluminescent images were analyzed using the Living Image 4.2 software (Caliper Life 
Sciences).  Identical regions of interest (ROI) were used to determine the average 
radiance (photons/sec/cm2/sr) of all images for all time points.  For tail vein injections, 
cells were maintained in exponential growth and were suspended in serum free culture 
media at a concentration of 5x107 cells/mL.  CB17/SCID mice were injected twice with 
100 μl of cell slurry with a 1 hour recovery time between injections.  Mice were 
euthanized 9-10 weeks post injections and analyzed by full necropsy.  Organs were 
analyzed for tumor cells using hematoxylin and eosin (H&E), and for the neuronal 
markers synaptophysin, chromogranin A and PGP9.5.  Digital calipers were used to 
measure tumor size. 
 
 
RT-PCR 
 
 Total RNA was extracted from xenograft tumors with an RNA kit (Qiagen, 
Valencia, CA) according to manufacturers’ recommendations.  Complementary DNA 
was prepared with the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) from 1 μg of 
RNA.  IQ Syber green Supermix (Bio-Rad) and oligonucleotide primers Casp8-F (5’-
AAGCAAACCTCGGGGATACT), Casp8-R (5’-GGGGCTTGATCTCAAAATGA), GFP-F 
(5’-CACATGAAGCAGCACGACTTCT), GFP-R (5’-AACTCCAGCAGGACCATGTGAT), 
Ubiq-F (5’-ACCTGACCAGCAGCGTCTGATATT), and Ubiq-R (5’-
TCGCAGTTGTATTTCTGGGCAAGC) were used to perform a two-step real-time PCR 
assay.  Samples were denatured at 95oC followed by an annealing and extension step at 
62oC.  Relative expression was quantified by the ΔCT method and normalized to either 
GFP or human ubiquitin. 
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CHAPTER 3.    ROLE OF CASPASE-8 PHOSPHORYLATION IN 
NEUROBLASTOMA 
 
 
Introduction 
 
 Activation of casp8 mediated by adaptor protein binding (i.e. FADD or TRADD) 
provides significant measure of control and regulation over the extrinsic apoptotic 
pathway.  Data demonstrates that binding partners such as inhibitor of apoptosis proteins, 
FLIP, and posttranslational modifications (i.e. ubiquitination, nitrosylation, and 
phosphorylation) add an increased measure of control over cell fate [107].  In regard to 
phosphorylation, both kinases and phosphatases control caspase activation and catalytic 
activity.  These caspase-regulatory pathways limit or promote an apoptotic response 
based on changes in the environmental queues, stressors, metabolism, and growth factors.  
A recent review outlined the molecular events of caspases (2, 3, 8, and 9) 
phosphorylation and the biological significance of such modulation.  Interestingly, the 
majority of phosphorylative events mediated by various kinases (i.e. DNA-PK, CaMKII, 
and Src) suppressed the catalytic activity of their caspase substrate [107]. 
 
 As previously stated, the various functions of casp8 may be regulated by 
localization, involvement with various macromolecular complexes, and/or 
posttranslational modifications [90, 99, 100].  Cursi et al. was the first to show that EGF-
mediated migration-induced casp8 phosphorylation by Src at Y380 [101].  This 
phosphorylation induced casp8 interactions with the p85 subunit of the 
phosphatidylinositol 3-kinase thereby increasing migration and adhesion.  Later, Barbero 
et al. demonstrated that integrin ligation could also induce casp8 phosphorylation at Y380 
and promote the localization of casp8 to the lamellae of migrating cells [102].  In 
addition, Cursi et al. further demonstrated that the phosphorylation event of Y380 
suppressed the catalytic activity of casp8 by approximately two-fold [101].  Caspase-8 
phosphorylation by cyclin-dependent kinase 1 (Cdk1) and ribosomal S6 kinase 2 (RSK2) 
at S387 and T263 respectively, led to a decrease in Fas-mediated apoptosis [103, 104].  
p38MAPK phosphorylation of casp8 at S347 also suppressed the catalytic activities of 
casp8 [105].  Ataxia telangiectasia mutated (ATM) kinase, phosphorylated casp8 at S219 
upon double strand DNA breaks, suggesting a possible crosstalk between DNA repair 
and apoptosis [106].  In cancer, several of these kinase are reported to be upregulated due 
to their prosurvival function.  This increased kinase activity may contribute to altering the 
balance between the canonical function of casp8 to a more noncanonical or prosurvival 
function [107]. 
 
 Cells are constantly exposed to natural DNA damaging signals that pose serious 
threats to genomic integrity [173, 174].  Evolutionarily, cells have adapted elaborate 
signaling networks which regulate cell cycle progression, DNA damage repair, and/or 
cell death.  DNA is subject to damage when exposed to reactive oxygen species (ROS), 
environmental chemicals, or exposure to ultraviolet radiation.  If DNA damage is left 
unrepaired and allowed to be propagated to subsequent daughter cells, it would be 
detrimental to the organism as a whole.  One particular form of DNA damage is double-
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strand break (DSB), in which both strands of DNA are severed.  This DNA damage 
requires a specific DNA damage repair mechanism. 
 
 Ataxia telangiectasia (A-T) is a rare autosomal recessive disorder derived from a 
mutated gene product, ATM [175].  Clinically, A-T patients manifest with 
radiosensitivity, immune dysfunctions, telangiectasia, and an increased frequency of 
cancer [176].  ATM, a serine/threonine kinase, is a member of the phosphatidylinositol 3-
kinase-related kinase (PIKK) family and composed of a PI(3)K domain, a FAT 
(FRAPP/ATM/TRRAP), and a FATC domain [177].  Most commonly, mutations of 
ATM reside within the FATC domain [178].  A-T patients may also present with immune 
dysfunction, radiosensitivity, meiotic defects, and cancer [179]. 
 
 DSBs recruit a heterotrimer complex known as the MRN complex (Mre11-
Rad50-Nbs1) which senses DNA damage and acts as the platform for ATM activation 
and DNA damage repair [180-182].  Binding of the MRN to DSB induces conformational 
changes of Rad50 promoting the tethering of the two breakage sites mediated by its 
flexible coiled coils and zinc-hook [183, 184].  The Mre11 possesses nuclease activity 
while the C-terminal region of ATM interacts to Nbs1, driving ATM activation [185, 
186].  ATM resides in the nucleus as an inactive homodimer.  Upon DNA damage, ATM 
interacts with the MRN complex and undergoes autophosphorylation, which reduces 
ATM to an active phosphorylated monomer [187].  Activated ATM can phosphorylate 
several cell-cycle regulators including p53, p21, Nbs1, Chk1 (checkpoint kinase 1) and 
BRCA1 (breast cancer 1, early onset).  In addition, ATM can signal for cell death via 
Chk2 (checkpoint kinase 2) and p53.  DNA damage repair can be mediated through 
KRAB-associated protein1 (KAP-1) and p53-binding protein 1 (53BP1) along with other 
repair proteins [188].  Overall, ATM can induce DNA damage repair, cell-cycle arrest, 
apoptosis, and has been known to play key roles in meiosis, homeostasis and cancer 
prevention [188]. 
 
 Further studies on ATM activation revealed that ROS also led to ATM activation; 
however, signal transduction varies.  Oxidative stress induces a disulfide bridge to form 
between the ATM homodimer.  This disulfide bridge inhibits ATM to separate into active 
monomers [187].  The active ATM homodimer induces an antioxidant response, as 
opposed to a DNA repair response.  The antioxidant response involves phosphorylation 
of heat-shock protein (HSP27); thereby leading to glucose-6-phosphate dehydrogenase 
(G6PDH) activation and an increase in nicotinamide adenine dinucleotide phosphate-
oxidase (NADPH).  Increased levels of NADPH are linked to cell survival, and 
proliferation, making NADPH a potential target for cancer therapy [178, 188-191]. 
 
 ATM is predominantly a nuclear protein; however, some studies report a 
cytoplasmic fraction of ATM. This suggests that ATM may have functions outside of 
DNA damage repair.  ATM is shown to interact with the peroxisomes, modulate synaptic 
and vesicular function.  In B cells, NF-кB stimulates the ATM-mediated phosphorylation 
of NEMO (NF-кB essential modulator), resulting in cytoplasmic relocation of the 
ATM/NEMO complex.  This complex interacts with the IкB kinase leading to NF-кB 
signaling [192-194].  In vivo studies of lymphocytes demonstrate that, upon DNA 
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damage, ATM is essential for NF-кB mediated transcription [195].  ATM has also been 
linked to insulin signaling through the phosphorylation of eIF-4E-binding protein 1 (4E-
BP1), while ATM deficiency is linked to defects in mitochondrial function and mice 
deficient for ATM demonstrate an increased resistance to insulin and onset of 
atherosclerosis and metabolic syndrome [196-199].  In response to ROS, cytoplasmic 
ATM decreases the responsiveness of mTORC1 (mTOR complex 1) and autophagy 
promoting the activation of tuberous sclerosis complex 2 (TSC2) and hypoxia-induced 
factor (HIF-1). 
 
 ATM-mediated cell death upon DNA damage is thought to be dependent on the 
extent of DNA damage.  Therefore, upon extensive DNA damage, ATM phosphorylates 
p53 at S15 leading to the optimal induction and activity of p53and induction of the 
intrinsic apoptotic pathway.  As a transcription  factor, active p53 mediates the 
transcription of various proapoptotic proteins, namely those of the Bcl-2 family, such as 
Bax, Puma, and Noxa [200].  At low concentrations of DSBs, ATM signals through 
NEMO, to induce NF-кB signaling and transduction of prosurvival genes such as cIAP 
and FLIP.  Increased DNA damage induces an increase in TNF-α transcription by NF-кB 
signaling.  TNF-α signaling through TNFR1 can transduce cell death mediated by casp8 
activation and recruitment to the RIP1 complex [194].  Death receptor-mediated 
apoptosis induced by either TRAIL or FasL transduces the apoptotic signal through the 
activation of casp8, though the expression of inhibitor proteins such as FLIP can block 
casp8 mediated apoptosis.  One study suggests that upon exposure to DNA damaging 
agents such as chemotherapeutic agents and/or IR induces DNA DSB and subsequent 
ATM activation.  ATM activation enhances the ubiquitination and degradation of the 
long isoform of FLIP; thereby sensitizing cells to TRAIL and FasL mediated apoptosis 
[201].  BID, a well-known substrate of casp8, is phosphorylated by ATM, which causes 
BID localization and accumulation in the nucleus leading to cell cycle arrest in S-phase.  
A nonphosphorylatable BID mutant showed no S-phase accumulation and increased the 
cell sensitivity to DNA damaging agents, suggesting that ATM phosphorylation can 
modulate the proapoptotic function of BID to initiate cell survival [202]. 
 
 Previous data suggests that casp8 phosphorylation by various kinases suppresses 
catalytic activity and promotes cell survival.  In this study, we hypothesized that the 
modulation of casp8 by phosphorylation promotes critical nonapoptotic functions 
during NB tumorigenesis.  We aim to determine whether the phosphorylation event 
mediated by ATM upon DNA damage promotes casp8 phosphorylation and alters the 
balance between the canonical apoptotic function of casp8 and its noncanonical 
prosurvival role.  We demonstrate that casp8 is phosphorylated at S219 in an ATM-
dependent manner and that phosphorylation suppresses the enzymatic function of casp8.  
In our model, we show that ATM phosphorylation has no significant effect on NB tumor 
cell engraftment or proliferation.  Additional studies demonstrating the potential 
biological effect of casp8 phosphorylation at S219 are required. 
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Results 
 
 
DNA damage promotes caspase-8 phosphorylation 
 
 A large-scale proteomic study by Matsuoka et al., demonstrated that casp8 is 
phosphorylated at S219 post DNA damage in an ATM-dependent manner [106].  To 
validate these findings we studied 293T cells and three NB cell lines expressing 
endogenous casp8 in response to 10 Gy of IR to induce DNA DSBs and subsequent ATM 
activation.  Cells were allowed to recover for one hour prior to lysis and 
immunoprecipitation of casp8.  Proteins were separated on an SDS-PAGE gel and blotted 
for phosphorylated casp8 (pCasp8) using the validated antibody recognizing the 
phosphorylated S78 epitope of BID (Figure A-1B).  Caspase8 phosphorylation was 
detected in all four cell lines post DNA damage, as opposed to our non-irradiated cells 
and our bead-only immunoprecipitated (IP) negative control (indicated as C)         
(Figure 3-1A).  Immunoblot analysis also revealed that ATM was activated, thus 
suggesting the possibility that ATM upon activation may phosphorylate casp8.  To 
determine whether phosphorylation of casp8 impacted apoptosis, casp8 S219 was 
mutated to either a nonphosphorylatable (S219A), or phospho-mimic (S219E) isoform.  
These constructs were stably transfected into NB7 and NB1691 cell lines.  Expression 
levels were similar to casp8wt expressing NB7 and NB1691 cells (Figure 3-1B).  We 
then exposed our NB7 and NB1691 cell lines containing the vector only, casp8wt, and 
our two phosphorylation mutants (S219A, S219E) to 10 Gy IR and probed for casp8 
phosphorylation.  Non-irradiated cells and beads-only served as negative controls and IP 
controls, respectively.  In both NB cell lines exposed to IR and expressing the casp8wt 
revealed that a fraction of the total casp8 pulled down was phosphorylated; while no 
phosphorylation event was detected in the non-irradiated casp8wt control or irradiated 
casp8 mutants (Figure 3-1C).  A kinase assay further confirmed casp8 phosphorylation 
upon ATM activation (Figure 3-1D).  The casp8 doublet is formed from two Kozak 
sequences, as discussed previously [164].  Interestingly, the larger of the two casp8 
constructs was phosphorylated at a higher frequency.  Overall, these data suggest that 
casp8 is phosphorylated upon DNA DSB at S219 and further validates the specificity of 
our antibody. 
 
 
ATM-mediated phosphorylation of caspase-8 
 
 Our previous results demonstrate that, upon irradiation, casp8 is phosphorylated 
as well as several other proteins.  Therefore, we set out to validate whether ATM 
mediates the phosphorylation of casp8 at S219 upon irradiation.  To test the role of ATM, 
we used a potent ATM inhibitor, Ku-55933, to block ATM activation upon DSB.  We 
exposed our NB cell lines expressing either wild-type or the nonphosphorylatable mutant 
form of casp8 to 10 μM of Ku-55933 for 30 minutes prior to exposure to irradiation 
(Figure 3-2A).  Our positive and negative controls consisted of casp8wt and casp8 
S219A cells exposed to IR.  NB7 and NB1691 lacked casp8 phosphorylation in casp8wt 
expressing cells when treated with IR plus inhibitor.  Clearly, upon exposure to  
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Figure 3-1. Caspase-8 phosphorylation at S219 post DNA damage. 
(A)  293T cells and three NB cell lines (SK-N-AS, NB16, NB5) were exposed to 10 Gy 
IR and analyzed for casp8 phosphorylation.  Lanes indicated with a C mark control wells 
comprised of  specific cell line exposed to IR and immunoprecipitated (IP) using beads 
only (without antibody).  (B)  Point mutagenesis of casp8 at S219 to either a 
nonphosphorylatable mutant (alanine) or a phospho-mimic mutation (glutamic acid).  
Expression levels of mutant casp8 in NB7 and NB1691 cell lines.  (C)  NB7 and NB1691 
cell lines expressing the various constructs of casp8 (wt, S219A, S219E) or vector only 
exposed to 10 Gy IR and blotted for casp8 phosphorylation.  (D)  Kinase assay 
demonstrating in vitro phosphorylation of casp8. 
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Figure 3-2. Caspase-8 phosphorylation at S219 is ATM dependent. 
(A)  NB7 and NB1691 cells lines expressing the indicated casp8 construct were exposed 
to 10 μM of the ATM inhibitor, Ku-55933, 30 minutes prior to exposure to 10 Gy of IR.  
(B)  Indicated NB cell lines expressing either vector control (vec), casp8wt, or the 
nonphosphorylatable mutant (S219A) were exposed to 75 J/m2 of ultraviolet radiation 
and lysed one hour post exposure.  (C)  Human fibroblasts from an ataxia telangiectasia 
patient (GM05823), null for ATM expression, were exposed to 10 Gy and probed for 
phosphorylation of casp8 at S219.  Normal human fibroblasts (BJ-5ta) and NB7-Casp8wt 
cells were used as positive controls. 
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Ku-55933 ATM activation was effectively blocked and casp8 phosphorylation was not 
detected, suggesting that phosphorylation of casp8 may be ATM dependent.  Work 
performed by Matsuoka et al and others demonstrated that ATM and ATR have similar 
phosphorylation sites and substrates [106].  One essential difference between these two 
kinases is the mode of activation.  ATR is primarily activated upon single strand DNA 
breakage, but is also responsive to ultraviolet radiation (UV) induced DNA crosslinking 
between cytosine and thymine bases (pyrimidine dimers) [203].  Therefore, we exposed 
our cell lines expressing the indicated casp8 construct to UV at 75 J/m2.  Cells exposed to 
IR (10 Gy) were included as positive controls.  Western blot analysis revealed that UV 
did not induce phosphorylation of casp8 in NB7 cells. By contrast, casp8 was 
preferentially phosphorylated in response to UV compared to IR (Figure 3-2B).  To 
further challenge the role of ATM in casp8 phosphorylation we analyzed GM05823 
human fibroblast cells derived from an ataxia telangiectasia (A-T) patient.  These cells 
are null for ATM expression.  Normal hTERT-immortalized human fibroblasts (BJ-5ta) 
and NB7 cells reconstituted with casp8wt were included as positive controls.  All cells 
were exposed to 10 Gy of IR and analyzed for casp8 phosphorylation by western blot.  
As shown in Figure 3-2C, ATM defective cells lacked casp8 phosphorylation whereas 
casp8 was phosphorylated in BJ-5ta and NB7 casp8wt cells (Figure 3-2C).  Taken 
together, these data support our hypothesis that casp8 phosphorylation is dependent on 
ATM activation. 
 
 
Caspase-8 phosphorylation is a cytoplasmic event 
 
 ATM is primarily known as a nuclear protein.  Some studies have demonstrated 
that ATM may become cytoplasmic and be involved in various cytoplasmic functions.  A 
caveat of these studies is that cytoplasmic ATM has only been shown in cell lines and has 
yet to be shown in vivo.  In contrast, casp8 is primarily cytoplasmic; though the N-
terminal, prodomain, and active subunit of casp8, have been shown to localize to the 
nucleus under certain conditions [108, 111, 112].  Therefore, in order to further study 
ATM and phosphorylation of casp8 we determined if this post-translational modification 
event was cytoplasmic or nuclear.  Control and IR-treated NB7 cells expressing the 
various constructs of casp8 were fractionated and blotted for casp8 and pATM.  The 
purity of the nuclear and cytoplasmic fractions was determined by blotting for both β-
lamin and α-tubulin, respectively.  Independent of DNA damage, casp8 remained 
cytoplasmic.  Long exposure of pATM revealed that a small fraction of ATM was located 
in the cytoplasmic fraction post DNA damage (Figure 3-3A).  This suggests that upon 
DNA damage, pATM enters the cytoplasm and induces the phosphorylation of casp8.  
Support for this data comes from work by Biton et. al. demonstrating that pATM and 
NEMO translocate to the cytoplasm upon ATM activation [194].  Our data does not 
clearly demonstrate the localization of phosphorylated casp8; thus we 
immunoprecipitated our cytoplasmic and nuclear fractions with and without exposure to 
IR and show that phosphorylated casp8 remains cytoplasmic (Figure 3-3B).  Taken 
together, our data indicates that the phosphorylation event of casp8 mediated by active 
ATM is a cytoplasmic event induced by a cytoplasmic fraction of ATM. 
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Figure 3-3. Phosphorylation of caspase-8 is a cytoplasmic event. 
(A)  Cell fractionation of NB7 cells deficient for casp8 or expressing either wt, S219A, or 
S219E mutations, were analyzed for cytoplasmic (C) or nuclear (N) localization of casp8 
post DNA damage.  (B)  Using the previous cell fractionations, cytoplasmic and nuclear 
fractions were immunoprecipitated for casp8 and detection of phosphorylated casp8 by 
western blot analysis. 
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Serine 219 of caspase-8 suppresses the catalytic activity 
 
 A review of the literature reveals that there are eight phosphorylation sites on 
casp8.  Phosphorylations of seven of these residues are mediated by known kinases and 
each suppress the apoptotic activity of casp8 by approximately two-fold.  We 
hypothesized that modulation of casp8 would switch casp8 from its canonical apoptotic 
function to a noncanonical pro-survival protein.  To investigate whether the catalytic 
activity of casp8 was affected due to phosphorylation, we exposed our NB7 cells 
expressing the various constructs of casp8, to TRAIL [50 ng/mL], MG132 [1 μM], and a 
proluminogenic substrate of casp8.  This proluminogenic substrate upon cleavage by 
casp8 emits a detectable luminescent signal that can be quantified [103, 104].  Cells were 
harvested at various time points post exposure to TRAIL and MG132, as indicated 
(Figure 3-4A).  At six hours NB7 casp8 S219E were significantly more resistant to 
apoptosis than casp8wt expressing cells (P < 0.004).  NB7 casp8 S219A cells were 
essentially as sensitive to the treatment as casp8wt expressing cells.  Cell death was also 
quantified by measuring the impedance level of a biosensor.  Cells are attached to gold 
electrodes at the bottom of 96-well plates.  A small current signal (1 μA) produces an 
electric field.  Impedance of the electric field by cells can be quantified and measured in 
real-time.  As indicated previously, cells were exposed to TRAIL and MG132 and 
subjected to real-time analysis of cellular impedance.  Supporting our luminescent study, 
NB7 casp8 S219E cells had a higher baseline delta cell index, suggesting that these cells 
were less likely to undergo apoptosis as compared to NB7 casp8wt and casp8 S219A 
cells (Figure 3-4B).  We propose that the phosphorylation at S219 may suppress the 
enzymatic activity of casp8 though not completely abolish it.  Exposure to TRAIL and 
MG132 for extended periods demonstrated that NB7 C8 S219E cells were just as capable 
to undergo apoptosis as casp8wt (Figure A-2A).  Overall, these data may suggest that 
ATM-mediated phosphorylation of casp8 may hinder casp8-mediated apoptosis under 
short exposure to apoptotic stimuli; thus allowing for ATM to drive DNA damage repair.  
Extended exposure to death-inducing stimuli (TRAIL) may overcome ATM-induced 
apoptotic hindrances and drive apoptotic cell death. 
 
 
3D culture demonstrated increased colony formation 
 
 NB7 and NB1691 cell lines were analyzed in vitro for changes in proliferation in 
response to wt and mutant casp8 expression.  Interestingly, casp8 expression had no 
effect on proliferation in control and IR-treated 2D cell culture in either NB cell line 
(Figure 3-5A and B).  In addition, the proliferation of cell expressing wt and mutant 
casp8 was similar when exposed to ROS and serum starved (data not shown).  Our 
orthotopic xenograft mouse model displayed clear difference in cell proliferation with 
and without casp8 (Figure 2-1B), suggesting changes in environmental conditions may 
affect casp8 role in tumorigenesis.  To address this issue in further detail, NB cells were 
suspended in a 3D collagen matrix and analyzed after three weeks in culture.  
Quantification of colony size demonstrated that within a 3D environment casp8wt and 
casp8 S219E expressing NB7 cells developed larger and more numerous cell colonies 
(Figure 3-5B).  These findings are consistent with the xenograft studies and suggest that  
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Figure 3-4. Phosphorylation at S219 suppresses caspase-8-mediated apoptosis. 
NB7 cells, deficient or expressing casp8 (wt, A219, E219), were treated with TRAIL [50 
ng/mL] and MG132 [1 μM].  (A)  The enzymatic activity of casp8 was analyzed using a 
luminogenic cleavage substrate.  Luminescent signal was measured at indicated times (*, 
P ˂ 0.004).  (B)  The catalytic activity of casp8 was measured using the xCELLigence 
system which measures cellular impedance in real time.  Cells are seeded at confluency 
and allowed to adhere to biosensor plated wells.  Confluent wells have the highest level 
of cellular impedance.  Cell death decreases the impedance.  The difference of impedance 
over time was measured at indicated times.  Control cells were NB7 cells expressing wt 
casp8 grown under normal conditions.  Experiments were performed in triplicate. Error 
bars, ± s.e.m. 
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Figure 3-5. Phosphorylation increased colony formation and growth. 
(A, B)  Proliferation of both NB7 and NB1691 cells expressing the various casp8 
constructs were exposed to various levels of IR and analyzed by MTT.  (C)  NB7 cells 
expressing casp8wt or a mutant form of casp8 and NB7 cells deficient for casp8 were 
suspended in a collagen matrix.  Cells were maintained in matrix for 3 weeks and 
cultured under regular culture conditions.  Colonies were counted and analyzed for size 
using the ImageJ Software.  Experiment was performed in triplicate (*, P ≤ 0.02 and **, 
P ˂ 0.002).  Error bars, ± s.e.m. 
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the role of casp8 in tumorigenesis may promote proliferation and be dependent on the 
microenvironment.  In addition, NB7 casp8wt and S219E cells demonstrated an increased 
affinity for adhesion to collagen coated plates, suggesting a possible mechanism between 
casp8 and integrins (Figure A-2B).  Stupack et al. demonstrated by co-
immunoprecipitation that casp8 associates with integrins, while Barbero et al showed that 
casp8 is phosphorylated upon integrin ligation; both studies supporting casp8 
involvement with integrins. 
 
 
Role of caspase-8 phosphorylation in NB tumorigenesis 
 
 We previously demonstrated that casp8 enhances tumorigenesis of NB cells and 
have shown that casp8 phosphorylation suppresses the enzymatic activity.  Therefore, we 
hypothesized that phosphorylation at S219 may modulate casp8 function within the cell 
thereby altering the proapoptotic function of casp8.  To investigate the possible role of 
casp8 phosphorylation in tumorigenesis, we orthotopically injected our NB7 cells 
expressing the nonphosphorylatable and phospho-mimic mutants of casp8 and our 
NB1691 cells expressing only the nonphosphorylatable casp8 mutant.  In NB7 cells at the 
seven week time point, we noticed no significant difference between the two mutant 
versions of casp8 in comparison to casp8wt (Figure 3-6A).  In addition, NB1691 cells 
expressing the alanine point mutation revealed no significant difference in tumor growth 
when compared to vector control and casp8wt tumors (Figure 3-6B).  Analysis of overall 
survival of tumor bearing mice confirmed previous results demonstrating that 
phosphorylation does not appear to affect NB tumor growth or overall survival in this 
model (Figure 3-6C and D).  Figure 3-6E is a representative image of the 
bioluminescent images obtained and quantified for the previously mentioned figures 
(Figure 3-6E).  We also injected NB7 cells with both the S219A and S219E point-
mutations into the flank of nude mice at the same cell concentration as our orthotopic 
model.  Mouse flank tumors were analyzed weekly by bioluminescence for ten weeks.  
Tumor growth data from our flank injected tumors were similar to the para-adrenal 
xenografts (Figure A-2C). 
 
 Previously, we noticed a significant difference in the ability of casp8 to enhance 
tumor engraftment and growth; hence we examined our NB7 and NB1691 cells 
expressing the mutant construct of casp8 for variances in tumor engraftment.  In support 
of our bioluminescent data, no significant differences were observed in overall tumor 
engraftment (Figure 3-7A and B).  Figure 3-7C and D are representative images of five 
randomly selected tumors derived from the indicated cell lines demonstrating that overall 
tumor engraftment and growth was not enhanced or decreased due to phosphorylation 
(Figure 3-7C and D).  Xenografts derived from either NB7 casp8 S219A or S219E were 
analyzed by hematoxylin and eosin (H&E) or probed for phospho-Histone H3.  We 
quantified positive nuclei using the Aperio Spectrum™ software (Figure 3-7E).  No 
significant differences were observed between the different mutant casp8 constructs. 
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Figure 3-6. Phosphorylation of caspase-8 did not enhance tumorigenesis. 
NB7 and NB1691 cells reconstituted with either nonphosphorylatable (S219A) or 
phospho-mimic (S219E) casp8 were orthotopically injected into the para-adrenal region 
of nude mice.  Comparison of NB cells deficient for casp8, expressing wt, or mutant 
casp8.  (A, B) Representation of the normalized bioluminescence imaging in 
orthotopically injected mice derived from NB7 or NB1691 cells expressing the indicated 
constructs of casp8.  (C, D)  Survival curve of tumor bearing mice.  Once mice reached 
tumor burden they were removed from the study.  (E)  Representative bioluminescent 
images of tumor bearing mice. 
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Figure 3-7. Phosphorylation did not affect tumor engraftment. 
(A, B)  After 10 weeks for NB7 and 6 weeks for NB1691 xenografts, mice not having 
reached tumor burden were euthanized and analyzed visually for solid tumor 
engraftment.  Comparison to NB7 and NB1691 with and without casp8wt as previously 
shown.  (C, D)  Orthotopic xenograft tumors randomly selected from the indicated cell 
lines.  Scale bar, 1cm.  (E)  Xenografts of NB7 cells reconstituted with either non-
phosphorylatable mutant (a, b), or a phospho-mimic casp8 mutation (c, d) were 
transplanted into the para-adrenal region of nude mice and hematoxylin and eosin stained 
(a, c) or stained for phospho-Histone H3 (b, d).  Quantification of positive phospho-
Histone H3 staining from five representative tumors. 
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Regulation of caspase-8 
 
 To determine in our orthotopic xenograft model if casp8 expression is affected by 
phosphorylation, we performed western blot analysis on tumors derived from NB7  
casp8 S219A and S219E cells (Figure 3-8A and D).  Quantification of casp8 expression 
levels was determined by densitometric analysis and normalized to the representative 
GFP expression and compared to the parental casp8 positive cell line                     
(Figure 3-8B and E).  Densitometric analysis revealed that casp8 phosphorylation did not 
affect expression levels in our xenograft model.  mRNA expression levels of casp8 were 
compared to the housekeeper gene, ubiquitin (Figure 3-8C and F).  These data are 
similar to our casp8wt studies and demonstrate that under these conditions and in this 
model that there is no significant difference, biologically, by phosphorylation of casp8 at 
S219. 
 
 
Discussion 
 
 In earlier studies, we demonstrated that the catalytic inactivation of casp8 
enhanced the tumorigenic property of casp8 positive NB7 cells.  Therefore, we 
questioned as to how the enzymatic activity of casp8 could be modulated in vivo; thereby 
elucidating a possible biological switch of casp8, altering casp8 to a transducer of 
prosurvival signaling events.  Literature searches revealed that casp8, as well as other 
caspases, have been shown to be phosphorylated which subsequently led to a decrease in 
the enzymatic potential of caspases, in general.  Overall, we hypothesized that the 
function of casp8 may be modulated by phosphorylation; thereby altering the balance 
between the canonical apoptotic and nonapoptotic functions of casp8.  This hypothesis is 
supported by work demonstrating that by rendering casp8 catalytically inactive via point 
mutation, that the embryonic lethality of casp8 knockout could be rescued.  During the 
process of wound healing, casp8 is preferentially silenced in sites proximal to the wound 
and later restored; thus demonstrating a mode of casp8 regulation and control.  During 
our investigation of possible phosphorylation sites that could modulate the catalytic 
function of casp8, a large-scale proteomic study was published which suggested that 
ATM induces the phosphorylation of casp8 upon DNA DSB [106].  Therefore, we 
analyzed the role of this phosphorylation site in regard to the role of casp8 in apoptosis 
and tumorigenesis. 
 
 Detection of phosphorylated casp8 required immunoprecipitation of casp8 
pulldown followed by a secondary pulldown of phosphorylated casp8 using an antibody 
raised against the ATM phosphorylation site of BID (S78).  Prior to the post-translational 
analyses in NB, we determined whether the S219 residue of casp8 was evolutionarily 
conserved (Figure A-1A).  Interestingly, S219 was conserved in casp8 in all species 
analyzed ranging from human to mouse.  The SQ ATM recognition epitope was absent 
only in dog and mouse.  From an evolutionary stand-point, this would argue against the 
possible phosphorylation event of casp8 by ATM plays an essential role in survival, 
demonstrating only to be evolutionarily conserved in higher mammals (primates).  To 
validate that the pBID antibody detects phosphorylated casp8, we designed two peptides  
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Figure 3-8. Posttranslational regulation of caspase-8 in S219A and S219E 
mutated caspase-8 expressing NB7 cells. 
Caspase-8 expression in tumor xenografts derived from NB7 cells expressing casp8 
S219A (A) and S219E (D).  Control lanes consist of parental cell lines reconstituted with 
either vector only or indicated casp8 construct.  Xenografts expressing the 
nonphosphorylatable (B) and the phospho-mimic (E) casp8 constructs were analyzed by 
densitometry for casp8 expression and normalized to the representative GFP expression 
level and compared to control cell line.  Relative expression of casp8 mRNA normalized 
to ubiquitin in S219A (C) and S219E (F) xenografts.  Xenograft numbers are the same 
for each experiment Error bars, ± s.d 
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comprising six to seven amino acids upstream and downstream of the human casp8 SQ 
site.  To represent a positive control, one peptide was designed with a phospho-serine 
residue while the other peptide served as a negative, nonphosphorylated control.  Peptides 
were run on an SDS-PAGE gel and analyzed for recognition by the phospho-BID 
antibody.  Our analysis revealed that the antibody clearly recognized the casp8 ATM 
epitope when compared to our nonphosphorylated peptide control (Figure A-1B and C).  
Furthermore, when we compared BID and casp8 ATM epitopes (S78 and S219, 
respectively) we find that sequences downstream of SQ are highly conserved.  Analysis 
of additional essential residues upstream and downstream required for ATM-mediated 
phosphorylation of serine revealed no other key residues; thus supporting that both the 
BID and casp8 ATM epitopes may be recognized by the same antibody. 
 
 We have confirmed casp8 phosphorylation using various cell lines with either 
endogenous or reconstituted wild-type or mutant casp8.  Using a well-known and potent 
inhibitor of ATM and A-T cell lines deficient for ATM expression, we determined that 
ATM, not ATR, modulates casp8 upon DNA damage.  In NB7 cells we confirmed that 
UV radiation did not promote casp8 phosphorylation.  Surprisingly, casp8 was 
phosphorylated in NB1691 cells upon exposure to UV.  We suspect that genetically the 
NB1691 cells may be more sensitive to DNA damaging agents; thereby leading to ATM 
activation and casp8 phosphorylation.  This phenomenon of casp8 phosphorylation upon 
UV DNA damage would be interesting to investigate in other NB cell lines.  Cell 
proliferation and cell cycle analysis post UV exposure may support our assumption that 
NB1691 are more sensitive to DNA damaging UV radiation.  Active ATM was indicated 
by western blot in both NB7 and NB1691 cells exposed to both IR and UV suggesting 
still the possibility that ATM may be inducing the phosphorylation of casp8.  In addition, 
we demonstrated in human NB cell lines that upon DNA damage that ATM translocates 
to the cytoplasm and mediates the phosphorylation of casp8 at S219.  Prior research has 
demonstrated that a small subset of ATM may be cytoplasmic or may translocate to the 
cytoplasm [192-194].  These studies were performed in cell lines which may acquire 
nonphysiological functions due to culture conditions.  To our knowledge, there are no 
published results demonstrating, in vivo, that ATM is cytoplasmic.  We must take into 
account that in vivo modeling may also present with slight genetic differences in protein 
signaling and protein-protein interactions which may alter some of the protein functions 
and cell phenotypes.  In our model, ATM-mediated phosphorylation of casp8 upon DNA 
damage would imply that ATM may regulate apoptosis by either promoting apoptosis 
due to extreme DNA damage or suppressing apoptosis in order to allow cells to repair 
damaged DNA.  In the case of ATM-mediated phosphorylation of BID, the latter 
possibility is true.  Therefore, to elucidate the biological significance of casp8 
phosphorylation in regard to promoting death receptor mediated apoptosis, we exposed 
our cells to TRAIL and MG132 and quantified the cleavage of a proluminogenic casp8 
substrate.  These experiments determined that upon phosphorylation, the catalytic activity 
was suppressed.  This is supported by previous results demonstrating that other kinases 
such as Src, Fyn, Lyn, RSK6 and p38 MAPK suppress casp8 catalytic activity [107].  
Interestingly, we noticed that there was a moderate suppression of TRAIL-induced 
apoptosis, representing approximately a two-fold reduction when normalized to controls.  
Similar findings have been previously reported, indicating that phosphorylation does not 
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abolish but merely slows that activity of casp8 allowing, in our model, for ATM to 
suppress apoptosis.  Additional research investigating whether this phosphorylation event 
suppresses apoptosis under different inducers of extrinsic apoptosis, namely FAS and 
TNF-α, may further confirm the functionality of casp8 phosphorylation.  Examination of 
the S219 residue of casp8, reveals that the serine residue is proximal to a key aspartic 
acid residue at 216 (D216).  Autocleavage of these aspartic acid residues stabilizes and 
promotes full activation of casp8 and phosphorylation may block cleavage at D216.  
Furthermore, phosphorylation may also induce conformational changes within the linker 
region; thereby blocking the activation site upon casp8 homodimerization. 
 
 Prior to orthotopically injecting our mutant casp8 expressing cell lines, we 
analyzed the cells in a 2D environment for cell growth.  Interestingly, we noticed no 
significant difference in growth kinetics either by MTT, to measure metabolic rate, or cell 
cycle analysis using propidium iodide (PI) and flow cytometry (Figure A-3).  In our 
xenograft models we noticed very dramatic differences in NB7 cells with and without 
casp8.  To address the contribution of extracellular matrix in the regulation of casp8 and 
consequently cell proliferation and survival, we suspended NB cells in a collagen matrix 
and colony formation.  After three weeks, NB7 cells expressing casp8, independent of 
wild-type or mutant, demonstrated significantly larger colonies.  Our 3D environment 
recapitulated our xenograft data and showed that casp8 not only enhanced colony 
formation but cell growth within a 3D environment.  Unfortunately, attempts to extract 
colonies from the collagen matrix were unsuccessful.  Additional work characterizing 
individual colonies for casp8 expression levels will be necessary to further challenge the 
working model that casp8 is selected against in tumors.  Work by Stupack et al. 
demonstrated that casp8 associates with integrins [145].  Taken together with our 
orthotopic and tail vein xenograft models and our 3D cell growth data, we propose that 
casp8 may function with integrins to transduce cell survival. 
 
 Xenograft studies revealed that the nonphosphorylatable and phospho-mimic 
casp8 mutants in NB7 and NB1691 did not significantly affect NB tumorigenesis.  
Caspase-8 enhanced NB7 tumorigenesis independent of whether it was wild-type or 
mutant casp8, thus giving support for our previous work.  We examined, by IHC, the 
xenografts derived from the NB7 cell line expressing the various casp8 constructs in 
order to determine if significant differences were observed.  Unfortunately, no significant 
differences could be elucidated between the different casp8 constructs either by H&E, 
casp3, phospho-Histone H3, and CD31.  No apparent differences were noted in NB1691 
cells reconstituted with either casp8wt and nonphosphorylatable casp8.  In regard to the 
overall survival and engraftment rates, independent of the phosphorylation status of 
casp8, revealed to have no effect on overall survival.  This observation may be due to the 
decreased expression of casp8, as discussed later, or the phosphorylation of casp8 at S219 
may be an enhancer; thus phosphorylation of S219 promotes the phosphorylation at other 
sites of casp8 thereby initiating cell signaling.  Such is the case where an unknown 
kinases phosphorylates casp8 at Y293, which promotes additional phosphorylation of 
Y397 and Y465 by Lyn kinase [107].  Therefore, ATM-mediated phosphorylation may 
just be a suppresser and regulator of apoptosis.  Additional research is required to fully 
elucidate the potential biological mechanism of casp8 phosphorylation at S219.  In 
 59 
addition, our tumor models may not be sufficiently sensitive to see minor differences 
conferred by phosphorylation of casp8.  In this study we focused on casp8 
phosphorylation as a potential mechanism to enhance NB tumorigenesis and developed 
studies to test tumor growth and development; however, the phosphorylational event of 
casp8 by ATM may have significance relevant to other key biological pathways not 
necessarily affecting tumorigenesis.  Therefore, to fully understand casp8 and casp8 
modulation in all facets of NB, additional research is required. 
 
 
Materials and Methods 
 
 
Cell lines 
 
 Human neuroblastoma, NB5, NB7, NB16 and NB1691 cell lines have been 
previously described [17, 128].  In brief, neuroblastoma (NB5, NB7, NB16, NB1691) cell 
lines were established by St. Jude Children’s Research Hospital.  All NB cell lines 
including SK-N-AS were maintained in RPMI 1640 supplemented with 10% FBS, 1% 
glutamine and 0.1% gentamicin (Invitrogen, Grand Island, NY).  293T were maintained 
in DMEM supplemented with 10% FBS, 1% glutamine.  All cells were maintained in a 
humidified atmosphere of 5% CO2 at 37oC.  NB7 and NB1691 cell lines were 
reconstituted with casp8 using the pMSCV_IRES_GFP retroviral vector.  Retrovirus 
supernatants were prepared as previously described [17, 172].  Briefly, NB cells were 
cultured with viral supernatants plus polybrene [4μg/ml].  Viral supernatant was replaced 
with fresh supernatant every 2 hrs for 6 total hours.  Infections were allowed to occur for 
a total of 72 hours at 37oC.  After 72 hours, cells were sorted for GFP expression.  
Collected cells were cultured for two weeks prior to being sorted again for GFP 
expression.  Luciferase expression in NB7 cells was accomplished using the 
pMSCV_Luc_IYFP construct packaged in the previously described retroviral 
transduction method.  For NB1691 cells, 3x106 cells were electroporated twice, with a 10 
second interval between voltages, at 200 volts with 30 μg of the pMSCV-LucSh-zeocin 
construct and selected for zeocin resistance [100 μg/mL]. 
 
 
Reagents 
 
 Mouse anti-casp8 (C15) was a gift from Dr. M. Peter [158].  Goat anti-actin (C-
11), goat anti-lamin B (M-20), mouse anti-alpha tubulin (TU-02) were obtained from 
Santa Cruz Biotechnology, anti-rabbit GFP (A-11122) was from Invitrogen, anti-rabbit 
BID (2002), cleaved casp8 (D391) and rabbit phospho-ATR at Ser428 (cat# 2853P) were 
from Cell Signaling.  Rabbit anti-ATM (Ab-3) was purchased from Calbiochem, rabbit 
anti-phospho-BID (S78) (A300-528A) from Bethyl Laboratories, rabbit anti-phospho-
ATM at Ser1981 (EP1890Y, Epitomics, Burlingame, CA) ATM inhibitor, Ku-55933 was 
purchased from Tocris Bioscience (Minneapolis, MN). All antibodies were used as 
recommended by manufacturer.  Caspase-8 mutations were developed by the 
QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) and manufacturer’s 
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recommendations followed.  Mouse trueblot was purchased from Rockland Scientific 
(18-8817-33). 
 
 
Immunoblotting 
 
 Cells were lysed in Nonidet P-40 lysis buffer (20 mM Tris (pH 7.5), 150 mM 
NaCl, 1 mM EDTA, and 0.5% Nonidet P-40) plus 1 mM PMSF, protease inhibitor 
cocktail (Roche, Mannheim, Germany) and phosphatase inhibitors (1 mM NaF, 1 mM 
Na3VO4, and 1 mM beta-glycerophosphate) for 5 minutes on ice followed by sonication.  
Lysates were centrifuged at 14,000 rpm for 10 minutes.  Supernatants were removed and 
total protein was quantified using the Bradford assay (Bio-Rad, Hercules, CA).  Proteins 
(30 μg) were separated using SDS-PAGE analysis.  Immunoblots were visualized using 
unlabeled primary antibodies and HRP-conjugated secondary antibodies.  Protein 
expression was detected using enhanced chemiluminescence from GE Healthcare 
(Pittsburgh, PA).  Quantification of band intensity was performed using the NIH ImageJ 
program. 
 
 Tumor samples were minced using a clean razor blade and suspended in ACK 
buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) for 1 minute on ice to lyse RBC 
and repeated in needed.  Tumors were subsequently washed with PBS and suspended in 
RIPA buffer (150 mM NaCl, 50 mM Tris (pH 8.0), 0.5% sodium deoxycholate, 0.1% 
SDS, 1% NP-40) plus protease inhibitor (Roche, Mannehim, Germany).  Tumor samples 
were maintained in RIPA buffer for 5 minutes on ice and sonicated until tumor dissolved.  
Protein concentration was determined using the Bradford assay (Bio-Rad, Hercules, CA).  
Proteins (30 μg) were separated using SDS-PAGE. 
 
 For immunoprecipitations, cells were lysed in Nonidet P-40 lysis solution 1 hour 
after exposure to either 10 Gy of irradiation using a 137Cs source (Gammacell40-
extractor, MDS Norton) or 75 J/m2 by a UV Strataliner 2400 (Stratagene).  Caspase-8 
was pulled-down from 1 mg of cell lysate using the C15 caspase-8 antibody bound to 
protein G agarose beads (Pierce # 20398) or cross-linking to A/G agarose beads using a 
Pierce cross-linking kit (cat#26147, Rockford, IL) and eluted from beads according to 
manufacture recommendation.  Protein G agarose beads were washed in Nonidet P-40 
lysis solution three times and suspended in SDS sampling buffer and boiled for 10 
minutes. 
 
 
Colony formation 
 
 NB7 cells were prepared in a single cell suspension at a concentration of 1x106 
cells/mL.  Collagen matrix was purchased from Millipore (cat #ECM675, Billerica, MA).  
Cell slurry (10 μL) was suspended in 100 μL of collagen and seeded into a 96-well plate.  
Cells were maintained in cell culture media and incubated in a humidified atmosphere of 
5% CO2 at 37oC for 3 weeks.  Colonies were randomly selected and imaged.  Size of 
each colony was analyzed using the NIH ImageJ Software, colonies smaller than 0.01 
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mm2 were excluded from study.  Experiment was repeated in 3 times in triplicate with an 
average of 15 images obtained and analyzed per run. 
 
 
MTT 
 
 Cells were cultured in 96-well plates under indicated conditions.  At various time 
points, spent medium was removed and replaced with 20 μl phenol red-free RPMI 1640 
containing 5% FBS and 0.5 mg/mL MTT for 3 hours at 37oC.  Isopropanol (200 μl) was 
added to dissolve the MTT formazan crystals.  Absorbance was measured at 570 nm and 
background at 690 nm. 
 
 
In vitro kinase assay 
 
 Purified recombinant caspase-8 protein was produced using the TNT Quick 
Coupled Transcription/Translation System (Promega, Madison, WI) following 
manufacturer recommendations.  To investgate caspase-8 phosphorylation in vitro, NB7 
cells were lysed in Nonidet P-40 lysis buffer 1 hour after being irradiated at 10 Gy.  
500ug of total cell lysate were incubated with 2 ug of ATM antibody for 3 hours at 4 oC.  
Protein G agarose beads (15 μL) were then added to lysate and incubated overnight at 4 
oC.  Beads were washed in lysis buffer and suspended in kinase buffer (40 mM Hepes 
(pH 7.4), 5 mM EGTA, 10 mM MgCl2, 100 mM NaCl, 2 mM Benzamide, 0.1 mM NaF, 
0.1 mM Na3VO4, 60 mM beta-glycerophosphate, 1 mM DTT).  Combined 10 μL of 
suspended beads with 5 μL of purified recombinant caspase-8 and 15 μl of kinase master 
mix (4x kinase buffer, 1 mg/mL acetylated BSA, 1 mM ATP, 0.3 uL 32P-γATP)  and 
incubated at room temperature for 30 minutes.  SDS loading buffer was added to each 
sample and boiled for 5 minutes and proteins separated on an SDS-PAGE gel and 32P-
γATP-labeled proteins were detected by autoradiography. 
 
 
Cell fractionation 
 
 Cells were washed in PBS, centrifuged and then suspended for 20 minutes on ice 
in lysis buffer (10 mM Tris (pH 7.5), 5 mM MgCl2, 1mM DTT, 0.1% Nonidet P-40, 1 
mM PMSF) plus protease inhibitor cocktail (Roche, Mannehim, Germany).  For 
phosphorylation studies, phosphatase inhibitors were added (1 mM beta-
glycerophosphate, 1 mM Na3VO4, 1 mM NaF).  Cells were then centrifuged for 10 
minutes at 2000 rpm and supernatant (cytosolic fraction) was saved.  Pelleted fraction 
was washed again in lysis buffer and centrifuged.  Supernatant was added to the cytosolic 
fraction and pellet was suspended in a secondary lysis solution of 10 mM Tris (pH 7.5), 5 
mM MgCl2, 0.25 M Sucrose, 0.5% Triton X-100, 1 mM PMSF, protease inhibitor 
cocktail and 1 mM beta-glycerophosphate, 1 mM Na3VO4, and 1 mM NaF for 
phosphorylation studies.  Lysates were centrifuged for 5 minutes at 2000 rpm.  
Supernatants were discarded and pellets were suspended in a third lysate solution (10 
mM Tris (pH 7.5), 0.25 M sucrose, 1 mM PMSF, protease inhibitor cocktail, and 1 mM 
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beta-glycerophosphate, 1 mM Na3VO4, and 1 mM NaF).  Cell fraction pellets were 
sonicated and layered on top of a 0.88 M Sucrose solution.  Cell fractions were 
centrifuged through the sucrose gradient at 2000 rpm for 20 minutes.  The top layer was 
carefully removed and maintained as the nuclear fraction. 
 
 
RT-PCR 
 
 Total RNA was extracted from xenograft tumors with an RNA kit (Qiagen, 
Valencia, CA) according to manufacturers’ recommendations.  Complementary DNA 
was prepared with the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) from 1 μg of 
RNA.  IQ Syber green Supermix (Bio-Rad) and oligonucleotide primers Casp8-F (5’-
AAGCAAACCTCGGGGATACT), Casp8-R (5’-GGGGCTTGATCTCAAAATGA), GFP-F 
(5’-CACATGAAGCAGCACGACTTCT), GFP-R (5’-AACTCCAGCAGGACCATGTGAT), 
Ubiq-F (5’-ACCTGACCAGCAGCGTCTGATATT), and Ubiq-R (5’-
TCGCAGTTGTATTTCTGGGCAAGC) were used to perform a two-step real-time PCR 
assay.  Samples were denatured at 95oC followed by an annealing and extension step at 
62oC.  Relative expression was quantified by the ΔCT method and normalized to either 
GFP or human ubiquitin. 
 
 
Caspase-8 enzymatic assay 
 
 The catalytic activity of caspase-8 was assessed using a Caspase-Glo 8 Assay kit 
(Promega, cat#G8200, Madison, WI) according to the manufacturer’s instructions.   
Briefly, neuroblastoma cells were seeded in 96-well plates at a concentration of 2.5x104 
cells/well and allowed to adhere overnight.  Cells were treated with 50 ng/mL of TRAIL 
and 1 uM of MG132 [204].  Caspase-Glo 8 reagent was then added following 
manufacturer’s recommendations and allowed to incubate for 1 hr at room temperature.  
Luminescence of each sample was measured at 0, 2, 4, 6, and 8 hrs using a plate reader.  
The growth kinetics of TRAIL (50 ng/mL) and MG132 (1 μM) treated NB7 cells were 
examined using the Real Time Cellular Analyzer (RTCA) (xCELLigence system; Roche, 
Basel, Switzerland) which measures a cell’s interaction or impedance of biosensors.  
Cells were seeded at an empirically determined concentration in a 16-well gold-
microelectrode E-plate and allowed to adhere overnight.  Following adhesion, cells were 
treated with TRAIL (Prospec, East Brunswick, NJ) and MG132 (Millipore, Billerica, 
MA) and cell impedance was monitored every 5 minutes for 4 hours. 
 
 
Orthotopic xenograft 
 
 Ultrasound-guided orthotopic xenograft procedures were previously detailed 
[154].  Briefly, cells were suspended in Matrigel (BD worldwide, Cat#354234, San Jose, 
CA) at a concentration of 2x104 cells/μL and kept on ice.  Using a VisualSonics VEVO-
770 High Frequency Ultrasound system (VisualSonics, Toronto, Canada), a 22 gauge 
catheter was inserted into the para-adrenal space through the back muscle of anesthetized 
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CD1 nude mice.  A Hamilton syringe loaded with 10 μL of cell suspension was guided 
steriotactically into the region between the kidney and adrenal gland and injected.  For 
tumor growth analysis, mice were injected (intraperitoneal) with 3 mg/mouse of Firefly 
D-Luciferin (Caliper Life Sciences) and imaged using the IVIS® 200 imaging system.  
Bioluminescent images were analyzed using the Living Image 4.2 software (Caliper Life 
Sciences).  Identical regions of interest (ROI) were used to determine the average 
radiance (photons/sec/cm2/sr) of all images for all time points.  For tail vein injections, 
cells were maintained in exponential growth and were suspended in serum free culture 
media at a concentration of 5x107 cells/mL.  CB17/SCID mice were injected twice with 
100 μl of cell slurry with a 1 hour recovery time between injections.  Mice were 
euthanized 9-10 weeks post injections and analyzed by full necropsy.  Organs were 
analyzed for tumor cells using hematoxylin and eosin (H&E), and for the neuronal 
markers synaptophysin, chromogranin A and PGP9.5.  Digital calipers were used to 
measure tumor size. 
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CHAPTER 4.    OVERALL SUMMARY AND FUTURE EXPERIMENTS 
 
 
Summary 
 
 Neuroblastoma survival rates have improved; however, despite advances in 
chemotherapies and treatments, patients diagnosed with advanced-stage NB have shown 
little to no improvement with less that 40% long-term survival rate [8].  Caspase-8 has 
been shown to be silenced in up to 70% of advanced-stage NB patient tumors, while 30-
50% maintained casp8 expression [17].  Significance of casp8 deficiency decreased 
chemotherapeutic drug sensitivity and enhanced metastatic cell survival by preventing 
integrin-mediated cell death [127, 128, 145, 153].  In contrast, casp8 expression enhanced 
cell migration, adhesion, and promoted ruffle and lamellipodial formation [88, 91, 149].  
Caspase-8 may also regulate cell cycle via the S6K pathway, NF-кB activation, and 
Erk1/2 activation [86, 87, 96, 101].  These processes were determined to be independent 
of the enzymatic activity required for apoptosis.  In chapter two we discussed and 
demonstrated for the first time additional tumorigenic properties of casp8.  We 
determined using reconstituted casp8 in NB7 cells that casp8 enhances tumor 
engraftment and tumor growth.  Extensive studies in NB1691 were not performed due to 
our preliminary studies demonstrating that casp8 did not enhance NB1691 tumor 
formation and/or growth.  Additional studies investigating the genetic differences and 
titering our cell number used in our xenograft model may demonstrate possible 
differences in NB1691 with and without casp8 in NB tumorigenesis.  Furthermore, we 
showed by rendering casp8 catalytically inactive via point-mutation, that the enzymatic 
activity is not required for casp8-mediated tumor growth and formation.  Surprisingly, the 
N-terminal domain or prodomain of casp8 is essential for tumorigenesis.  This would 
suggest that casp8 must bind an adaptor protein (FADD or TRADD) to mediate its 
prosurvival function and promote tumorigenesis.  Supporting other published data, casp8 
was silenced at an unknown time point during tumorigenesis.  This would suggest a new 
avenue for additional research, to define the temporal regulation of casp8 expression 
using our orthotopic xenograft model.  In human patient samples, casp8 is predominately 
silenced by hypermethylation; yet, in our xenograft models NB cells seemingly regulate 
casp8 at either the translational or posttranslational level.  Additional experiments 
including pulse chase studies, polysomal preps, and ubiquitin bloting may elucidate the 
exact level of casp8 regulation in our NB xenograft models.  Since casp8 expression in 
NB7 cells enhances tumorigenesis and casp8 expression is downregulated by ten weeks, 
casp8 may be essential during the early phases of tumorigenesis and not be required once 
tumor establishment has occurred.  Analysis of xenografts harvested at different time 
points post-transplantation should provide additional insight into the mechanism by 
which casp8 contributes to tumorigenesis. 
 
 Previous research showed that protein kinases including Src, ATM, p38 MAPK 
and Cdk1, modulate and regulate casp8 activity and cellular function.  In general, 
phosphorylation reduces the enzymatic activity of casp8.  In hepatocellular carcinoma, 
breast and colon cancer elevated levels of phosphorylated casp8 were found, suggesting 
that the phosphorylation of casp8 may enhance tumorigenesis and/or metastasis [101, 
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103].  Our research suggests that casp8 is phosphorylated by ATM at S219 upon DNA 
damage.  This was demonstrated by extensive western blot analysis using various DNA 
damaging reagents, an ATM inhibitor, and human fibroblasts (null for ATM).  
Characterization of phosphorylated casp8 in NB tumorigenesis revealed no significant 
differences in either tumor growth or establishment.  Independent of the phosphorylation 
status of casp8, NB7 cells expressing casp8 had a higher frequency of tumor engraftment 
and tumor growth, supporting our previous data.  Phosphorylation of casp8 at S219 did 
show a suppressive effect of its enzymatic activity.  This may be a potential model for 
ATM to regulate extrinsic apoptosis upon DNA damage; which would allow cells to 
repair DNA.  Furthermore, independent of the phosphorylation status of casp8, western 
blot analysis revealed that casp8 is downregulated in late stage NB. 
 
 Based on this work and work performed by others, we suggest that the overall 
function of casp8 in NB may be at the early stages of tumorigenesis by enhancing tumor 
cell establishment and proliferation.  We have demonstrated that casp8 expression in 
NB7 cells enhanced tumor engraftment in our orthotopic and tail vein mouse models.  
Studies suggest that cells positive for casp8 along the periphery of the tumor are more 
sensitive to apoptosis due to their involvement in IMD.  Furthermore, seeding in a foreign 
secondary environment promotes casp8 expression, suggesting that those cells that can 
effectively suppress casp8 may be more metastatic.  Consistent with this hypothesis 
casp8 expression in the secondary tumor, once established, is downregulated         
(Figure 4-1). 
 
 Interestingly, casp8 effects on tumor cell proliferation were only observed in a 3D 
environment, xenografts or a collagen matrix.  Previous data demonstrated direct 
involvement of casp8 with integrins and casp8-mediated signaling induced by EGF 
stimulated integrins.  Ligand binding to a death receptor promotes casp8 recruitment and 
subsequent activation leading to cell death.  Stimulation of integrins based on cell 
environment may block casp8-mediated apoptotic signaling or promote casp8 non-
canonical survival functions.  Cells and tumor cells alike are constantly exposed to DNA 
damaging agents and stressors such as hypoxia, starvation, and ROS, which may lead to 
ATM activation and subsequent regulation of casp8.  Though ATM-mediated regulation 
of casp8 only suppresses the extrinsic apoptotic pathway, this suppressive affect may 
enhance cell survival under stressful conditions (Figure 4-2).  These findings suggest one 
potential mechanism as to why some tumors are less sensitive to DNA damaging 
chemotherapies. 
 
 Overall, casp8 appears to be a multi-functional protein playing key roles in two 
opposing processes; cell death and survival.  The factors and signals that influence these 
processes likely involve changes in protein complexes, homodimerization versus 
heterodimerization, and modification of casp8.  Elucidating the mechanism by which 
casp8 is regulated and functions in cancer will be important in developing new 
chemotherapeutics and improving outcome for patients with NB. 
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Figure 4-1. Role of caspase-8 in neuroblastoma. 
A cartoon representation of the possible casp8 expression levels at various stages tumor 
development, as suggested in the literature and current research. 
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Figure 4-2. Model of caspase-8 induced signaling. 
A model representing two potential modes of casp8 activation and their downstream 
signal transduction. 
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Future Directions 
 
 
Mechanism of caspase-8 during tumorigenesis 
 
 As previously stated, our research suggests that casp8 promotes early phase 
tumorigenesis by enhancing tumor establishment/colonization and growth of NB.  To 
confirm the role of casp8 in early primary tumor formation, we propose time course 
studies involving the extraction of primary tumor masses at specific stages post 
orthotopic injection into nude mice.  These tumors would be monitored by ultrasound for 
tumor volume and by bioluminescence for growth kinetics.  Simple western blot and 
quantitative real time PCR analyses of harvested tumors based on time points and size 
may elucidate when casp8 expression is downregulated.  Elucidation of exact stages 
during tumorigenesis at which casp8 is downregulated may identify other key events (i.e. 
angiogenesis, growth, metastasis, etc) occurring during that time point which may give 
insight as to the possible mechanistic roles of casp8 in tumor growth. 
 
 Knockout of casp8 in mice is embryonically lethal due to malformation of the 
heart and poor vascularization, giving rise to the possibility that casp8 may promote 
angiogenesis.  Visually, we noted that casp8 positive tumors were more angiogenic based 
on increased tumor vasculature in comparison to vector control NB7 cells.  
Unfortunately, we were unable to confirm these findings by stain for an endothelial cell 
marker (CD31).  Expanding our endothelial and angiogenic probes to include CD34, 
CD105, vWf, and VEGF may validate our visual analysis of our NB xenografts.  
Including both the chick chorioallantoic membrane (CAM) and the Matrigel plug assay 
using NB cells with and without casp8 would further validate the potential role of casp8 
in NB angiogenesis. 
 
 Our xenograft model suggests that casp8 expression is downregulated by the end 
of our ten week study.  This issue may be addressed by establishing tumor explants or 
cell line cultures short term in vitro and casp8 expression monitored by pulse-chase 
analysis with and without proteasomal inhibitors.  Earlier attempts were made to 
determine if casp8 was downregulated by protein degradation as determined by western 
blot analysis for ubiquitin.  This method was technically difficult due to the extremely 
high background levels of casp8 pull downs and poor ubiquitin antibodies.  
Immunoprecipitation of tagged casp8 may decrease background and allow for ubiquitin 
blotting. 
 
 The next critical aspect of characterizing the function of casp8 in tumorigenesis is 
to elucidate the mechanism and signaling pathways induced by casp8.  Mechanistically, 
casp8 has been shown to have a higher affinity for FLIP heterodimerization as opposed to 
homodimerization with casp8.  It has been suggested that casp8 homodimerization 
transduces apoptosis while heterodimerization mediates cell survival, due to FLIP 
inability to induce the intersubunit cleavage events of casp8.  Currently, we have 
constructed an N and C-terminal FLAG tag construct of casp8 for pulldown experiments.  
This construct can be transiently transfected into our NB cell lines and analyzed under 
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various stressors (i.e. hypoxia, IR, and lack of nutrients, etc) for heterodimerization.  To 
investigate casp8 heterodimerization using FLAG to pulldown casp8 within a 3D 
environment, we would need to design tagged casp8 into a retroviral vector.  Our studies 
have shown that cell culture within a 3D collagen matrix mimicked tumor xenograft 
studies.  Therefore to investigate the dimerization status of casp8 within a 3D 
environment we would use a proximity ligation assay (PLA) [205].  This assay works 
similarly to FRET where only upon close proximity of the two proteins of interest 
promotes the fluorophore to become excited.  Pulldown studies and PLA assay would 
identify the possible interactions of the known proteins to interact with casp8.  In 
addition, if casp8 heterodimerization was shown to be relevant during colony formation, 
crossing FLIP knockout mice with casp8 knockout would demonstrate if the embryonic 
lethality of both casp8 and FLIP knockouts were dependent on their heterodimerization.  
David Wallach’s lab demonstrated that by rendering casp8 catalytically inactive the 
embryonic lethality of casp8-/- mice could be rescued.  Essentially, heterodimerization of 
casp8 to FLIP suppresses the enzymatic activity of casp8 and essentially promotes a 
nonapoptotic response.  Therefore, we would hypothesis that casp8/FLIP 
heterodimerization is essential in promoting the prosurvival and subsequent 
protumorigenic function of casp8. 
 
 As previously stated several strategies have been developed to upregulate and 
promote casp8 as a potential therapeutic target for cancer therapy.  Since casp8 is most 
commonly epigenetically silenced in cancers, as opposed to mutated or deleted, treatment 
options include the use of 5-Aza, IFN-γ, and RA [116, 127, 139]  Though inducing casp8 
expression may present an attractive therapeutic target due to its apoptotic function, it 
may also promote survival.  Research shows that casp8 expression can be elevated in 
some tumors and some malignant tumors may tolerate high levels of casp8.  Furthermore, 
given the intense selective pressures present in the tumor microenvironment, upregulation 
of casp8 may promote the noncanonical prosurvival roles of casp8.  In such situations, 
increasing casp8 may be detrimental [141, 142].  Additional studies driven to understand 
the potential role of casp8 in chemotherapeutic responses would prove valuable in our 
xenograft model.  In our current study, we studied casp8 in response to IR and 
demonstrated that casp8 was phosphorylated upon DNA damage; however, we were 
unsuccessful to test this phosphorylation event in our xenograft model.  Previously, we 
irradiated mice bearing NB7 casp8wt xenografts and probed tumor lysates for 
phosphorylated casp8.  Due to the high background it was difficult to determine if casp8 
in our xenografts was phosphorylated.  We propose that by tagging casp8 with either 
FLAG or HIS may allow for cleaner IPs and easier detection of casp8.  Detection of 
casp8 phosphorylation in vivo would enhance the clinical significance of casp8 
phosphorylation upon DNA damage.  In addition to IR, examination of other DNA 
damaging agents that are commonly used in the clinic (etoposide, cisplatin, etc.) may also 
clarify the potential role of casp8 in therapeutic resistance/sensitivity. 
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Phosphorylation of caspase-8 
 
 My research has focused on primarily on S219 phosphorylation and its effect on 
cell survival and tumor growth.  Caspase-8 is posttranslationally modified at multiple 
sites. Prior to our investigation of ATM-mediated phosphorylation of casp8, we 
determined possible phosphorylation sites of casp8 using several online phosphorylation 
site calculators.  Several of these sites, some of which had been previously shown in the 
literature, were mutated at the phosphorylation site.  All constructs have been generated 
and confirmed by DNA sequencing.  Previously, we planned to stably express these 
constructs in NB cells lines and analyzing the cells for cell growth in order to determine 
which sites produced the greatest phenotype in our orthotopic and tail vein tumor models.  
One additional measure we would add to these studies, based on previous experience, 
would be to grow these cells in a 3D matrix.  Those sites which demonstrated either the 
greatest or lowest growth, as compared to vector only controls, would be analyzed for 
possible kinase involvement, mechanism of phosphorylation, and overall phenotype due 
to the phosphorylation status.  Binding kinetics of phosphorylated casp8 to casp8, 
phosphorylated casp8, and FLIP would be analyzed based on the model by Oberst et al. 
using an inducible binding prodomain [56].  Phosphorylated casp8 at Y360 and at S387 
have previously been determined in patient samples presenting with breast and colon 
cancer, suggesting that the phosphorylation of casp8 may enhance tumorigenesis and/or 
metastasis [101, 103].  Evaluation of casp8 phosphorylation at S219 in human patient 
samples would increase the validity and importance of casp8 in tumorigenesis. 
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APPENDIX.  CHAPTER 3 SUPPLEMENTAL FIGURES 
 
 
 
 
 
Figure A-1. Serine 219 of caspase-8 is highly conserved. 
(A)  Comparison of the S219 residue of human casp8 to other species.  (B)  Peptide 
sequence and western blot analysis of custom peptides.  (C)  Comparison of the BID S78 
to the S219 epitopes of casp8. 
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Figure A-2. Caspase-8 phosphorylation in apoptosis, adhesion and tumor growth. 
(A)  NB7 cells deficient, expressing wt or a mutant construct of casp8 were exposed to 
MG132 [1 μM], TRAIL [50 ng/mL], or both for 24 hours and blotted for cleaved casp8 
or downstream effects of active casp8, cleaved BID.  (B)  Adhesion assay performed in 
real-time to collagen coated plates [10 μg/mL].  Assay performed using the xCELLigence 
system.  (C)  NB7 cells expressing the indicated casp8 constructs were injected into the 
flank of nude mice at a concentration of 2x105 cells/mouse and analyzed by 
bioluminescence weekly, data shown here at the seven week time point. Error bars, ± 
s.e.m. 
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Figure A-3. Caspase-8 expression does not affect cell cycle. 
Casp8 expression did not significantly affect cell cycle.  NB7 cells expressing either 
vector (vec) or casp8wt or mutant (S219A) were synchronized using amphidicolin [5 
μg/mL], washed and suspended propidium iodide and analyzed by flow cytometry.  Cell 
were analyzed every two hours for 24 hours total, shown here are just the representative 
12 hour time points. 
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